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Resistance to glucocorticoid (GC) therapy results in poor prognosis for acute 
lymphoblastic leukemia (ALL) patients. Utilizing a whole genome shRNA screen 
our lab identified several novel mechanisms of GC resistance. My thesis work 
established that an orphan nuclear receptor, the Estrogen Related Receptor Beta 
(ESRRB), is critical for induction of apoptotic genes following treatment with the 
GC dexamethasone. ESRRB has mostly been implicated in maintenance of 
pluripotency in mouse embryonic stem cells. We find that repression of ESRRB 
results in GC resistance in ALL and define ESRRB as a novel cooperating 
transcription factor in GC-induced gene expression. We also show that agonists to 
ESRRB synergize with dexamethasone and increase dexamethasone induced 
apoptosis in relapse ALL patient samples. 
Interestingly, our shRNA screen identified another factor important in stem cell 
maintenance: SOX2. While we originally hypothesized that ESRRB and SOX2 may 
cooperate in ALL, RNA-sequencing studies revealed that these factors mediate 
GC resistance by independent mechanisms. Our data define SOX2 as a repressor 
of key signaling pathways in ALL. Upon SOX2 knockdown, we observe activation 
of pro-survival gene expression including activation of the MAPK pathway, which 
has previously been implicated in GC resistance. MAPK activation may be 
explained by an increase in EGFR expression observed in Sox2 knockdown cells 
and GC resistant patients, suggesting EGFR inhibitors may re-sensitize patients 
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T-cells are an essential component of the mammalian immune response 
and are generated by differentiation of hematopoietic stem cells. T-cell 
development occurs in the thymus after thymic seeding progenitors (TSPs) or early 
thymic progenitors (ETPs) derived from HSC arrive from the bone marrow. Cell 
migration from the bone marrow to the thymus is controlled in part by chemokine 
signaling from CCR9 and CCR71. These cells then enter the thymus at the cortico-
medullary junction2. ETPs have the potential to differentiate into T-cells, B-cells, 
natural killer cells, and dendritic cells; however, NOTCH1 signaling maintains T-
lineage potential3,4.  
The NOTCH family consists of a receptor made up of NOTCH1-4, which 
mediates transcriptional changes following binding of delta-like jagged ligands. In 
the thymus delta-like ligands Dll1 and Dll4, as well as jagged ligands Jag1 and 
Jag2 are expressed in the thymus and mediate activation of NOTCH1 signaling5. 
Following ligand binding the NOTCH receptor is activated and undergoes 
successive cleavage steps. First, a metalloprotease (ADAM10) cleaves the 
receptor at a site close to the membrane. Following this event, NOTCH is cleaved 
within the transmembrane domain by GxGD aspartyl protease Presenilin, which is 
part of a multi-protein complex termed Gamma Secretase. This releases the 
NOTCH Intra-cellular Domain (NICD), which can translocate to the nucleus to 
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mediate gene expression changes6. Importantly, in thymocyte development 
NOTCH1 is critical, but NOTCH3 has been shown to be dispensable7.  
 T-cell development proceeds in the thymus through a multi-step process. 
Each developmental stage can be characterized by cell surface receptors present 
or absent on the thymocytes. In the cortex, cells mature from ETPs to double 
negative (DN) thymocytes, as defined by absence of the cell surface markers CD4 
and CD8. DN thymocytes can be further categorized into DN1, DN2a, DN2b, 
DN3a, DN3b and DN4. In mice, DN1 cells are marked by high CD44 expression 
and low CD25 expression, DN2 cells are marked with high CD44 and high CD25, 
DN3 cells are defined by CD25 high and CD44 low cell surface expression and 
finally DN4 cells have low expression of both CD25 and CD448. The DN2 stage 
can be further sub-divided into DN2a and DN2b by C-KIT expression and DN3 
cells separate into DN3a and DN3b by cell size and CD27 expression9. Progress 
through the DN stages of thymocyte development involves signaling from key 
transcription factors and signaling pathways including NOTCH, signaling by WNT1 
and 4, and IL-73,10. The first phase of DN thymocyte differentiation involves the 
transition from ETP to DN2a, this stage involves rapid proliferation mediated by 
NOTCH1 signaling and the TCF1 and GATA3 transcription factors11. Cells then 
transition to DN2b, which is in part regulated by BCL11B. RUNX1 and E2A 
mediated gene expression changes facilitate the development from DN2b to the 
DN3 stage. In the DN3 stage of thymocyte development, cells begin to signal 
through their pre-T-cell receptor and undergo Beta selection12. Beta selection 
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refers to the beta chain of the T-cell receptor and indicates that the gene has 
successfully rearranged its Vb and Jb segments via recombination activating gene 
(RAG) mediated recombination events. If successfully rearranged this will lead to 
expression of a pre-T-cell receptor protein consisting of a Pre-Ta chain and TCRVb 
protein on the cell surface13.  
 DN3 thymocytes differentiate into DN4 and then double positive (DP) 
thymocytes which are defined by cell surface expression of both the CD4 and CD8 
receptors. Several transcription factors are essential in this step including TCF1, 
BCL11B, GATA3, E2A, HEB, ID3 and RORgt. These cells are no longer dependent 
on NOTCH1 signaling and will undergo rearrangement of the Va, Ja and Ca gene 
segments that encode the alpha chain of the T-cell receptor12.  
 DP thymocytes now undergo positive and negative selection in the medulla 
of the thymus. Positive selection involves successful TCR-MHC interaction to 
induce pro-survival signaling and prevent programmed cell death. Negative 
selection eliminates any T-cells that are self-reactive13. Cells will then 
downregulate either CD4 or CD8 to become CD4- single positive T-cells or CD8-
SPT-cells. ThPOK, TOX and GATA3 signaling encourage differentiation to the 
CD4 lineage, while NOTCH and RUNX3 signaling leads to CD8 specification3. 






T-ALL- oncogenes/tumor suppressors 
 
T-cell development is controlled by various transcription factors and 
signaling pathways. Unfortunately, at multiple points in T-cell differentiation the 
cells can undergo transformation leading to malignancy. Malignant transformation 
of thymocytes is characterized as T-cell acute lymphoblastic leukemia or T-ALL. 
T-ALL accounts for 25% of total ALL cases, with 75% of ALL cases resulting from 
malignant transformation of B-cells. 80% of ALL cases occur in children; however, 
adults diagnosed with ALL have a long-term remission rate of only 30-40%, this is 
in contrast to remission rates of 85% in children14. ALL patients present with bone 
marrow failure, easy bleeding/bruising, and infection, as well as potential 
splenomegaly and lymphadenopathy. Importantly, pediatric T-ALL patients may 
present with a thymic mass.  An ALL diagnosis requires 20% leukemic blasts in 
the bone marrow or peripheral blood15.  
In order to ensure the best therapeutic strategies, it is important to 
understand the underlying genetic events leading to thymocyte transformation. 
The most common oncogenic signal in T-ALL is constitutive NOTCH1 signaling. 
65% of patients exhibit activating mutations in NOTCH1 and 20% of patients 
exhibit mutations in FBXW7, which is essential for normal degradation of 
NOTCH116. Most patients exhibit mutations in the negative regulatory region 
(NRR) or PEST domain of NOTCH1. The NRR structure is essential for preventing 
cleavage of the intracellular domain in the absence of ligand17. Furthermore, PEST 
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domain mutations interfere with normal proteasomal degradation of NOTCH118. 
NOTCH1 signaling is key in normal thymocyte development; however, aberrant 
NOTCH1 signaling as a result of NRR and PEST domain mutations leads to 
stabilized intracellular Notch1 expression and thymocyte transformation. Typically, 
NOTCH1 requires ligand binding by delta-like or Jagged ligands. This allows 
cleavage at the extracellular membrane by ADAM10 and release in the NICD/ICN1 
by the Gamma Secretase Complex. ICN1 regulates expression of several target 
genes by binding with DNA binding protein RBPJk and recruitment of co-activator 
proteins19. Mutations in the NRR allows for ligand-independent signaling, while 
PEST domain mutations stabilize the ICN1 protein, allowing these mutations to act 
synergistically20. Activation of MYC by ICN1 occurs by direct binding to the c-myc 
promoter and via a long-range enhancer element located 1.27 Mb from the 
promoter in mouse T-ALL and 1.43 Mb from the promoter in human T-ALL21,22. 
MYC regulates cell-type specific gene expression signatures23,24 and in T-ALL  
activates glycolysis and glutaminolysis to support rapid proliferation16. Activated 
NOTCH1 also supports the pro-survival PI3K-AKT-MTOR pathway, promotes cell 
cycle through upregulation of CDK4/6, and T-cell survival through activation of NF-
kB (Nuclear Factor kappa-light-chain enhancer of activated B-cells) signaling25.  
 While NOTCH1 activation is a very common genetic alteration in T-ALL 
there are several other drivers of T-cell transformation. Increases in JAK-STAT 
signaling is observed in 33% of T-ALL patients, with activating mutations identified 
in JAK1, IL7R, JAK3, and STAT5B26.  Increased activity of this pathway results in 
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enhanced expression of MYC through promoter binding by STAT3 and anti-
apoptotic BCL-XL27,28. Furthermore, activation of the pro-survival PI3K-AKT-
MTOR signaling axis is a defined aberration in T-ALL, attributed to mutational loss 
or inactivation of the PTEN tumor suppressor. PTEN functions to attenuate AKT 
signaling and is mutated or repressed in T-ALL29,30. PTEN opposes PI3K/AKT 
signaling by hydrolyzing the key second messenger PIP3 to PIP2 preventing PIP3 
activation of AKT31. 
Alterations in cell cycle control have also been observed in T-ALL, with loss 
or deletion of the CDKN2A locus, which encodes p16INK4a and p14ARF tumor 
suppressors. These deletions are present in 70% of T-ALL patients, making it the 
most prevalent genetic abnormality in the disease32. P16INK4a inhibits the activity 
of CDK4/6 allowing cell cycle arrest, while P14ARF directly interacts with MDM2, 
promoting its degradation and allowing accumulation of the P53 tumor 
suppressor33. 
The PRC2 complex is another tumor suppressor in T-ALL. 25% of patients 
exhibit loss of function mutations in genes encoding the subunits of this complex, 
EZH2 and SUZ12. This complex could function to repress NOTCH1 mediated 
gene expression, indicating that a loss allows increased oncogenic signaling. 
Consistently the majority of patients that exhibit mutations in EZH2 and SUZ12 
also exhibit activated NOTCH134.  
Another key group of T-ALL patients exhibit activation of HOXA9/10 driven 
by the translocation and proximity to the TCR enhancer (Inv(7)p15q34)35. This 
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event is observed in 5% of pediatric patients and 8% of adult cases36. HOXA genes 
are oncogenic and can cause differentiation arrest37,38.   
Additional homeobox genes are involved in oncogenic transformation of T-
ALL, including TLX1 and TLX3. TLX1 overexpression results from a common 
translocation event involving TCRA/D. This event occurs in 5-10% of pediatric T-
ALL and 30% of adult T-ALLs32. TLX1 activation is oncogenic due to loss of the 
mitotic checkpoint and frequent aneuploidy39. A family member to TLX1, TLX3 is 
overexpressed in 20-25% of pediatric T-ALL cases and only 5% of adult T-ALL 
cases. This overexpression occurs due to a translocation that places TLX3 under 
control of the BCL11B locus, a gene critical in thymocyte development32. Recently, 
TLX3’s oncogenic role was characterized and found to activate miR-125b to cause 
differentiation arrest and proliferation40. Other oncogenes in T-ALL include NKX2-
1, NKX2-2, and MEF2C. These genes are activated by genetic rearrangements, 
although their exact role in oncogenic transformation is unclear41. 
 Lastly, overexpression of bHLH transcription factors and LIM domain 
proteins are frequent oncogenic signals in T-ALL. Overexpression of the bHLH 
factor TAL1/SCL is observed in 40-60% of T-ALL cases and aberrant TAL1 
expression leads to changes in expression of several genes involved in T-cell 
differentiation, cell survival and proliferation42. Chromosomal translocations 
involving the LIM domain proteins LMO1 and LMO2 lead to aberrant expression of 
these oncogenic proteins. There is evidence that these proteins are malignant due 
to regulation of thymocyte self-renewal by inducing expression of Lyl1, Hhex, Kit, 
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and Nfe243. Deregulation of LMO1/LMO2 is frequently found with activation of 
TAL1 or LYL132. A summary of prevalent mechanisms of leukemic transformation 
in ALL can be found in Figure 1.2. 
 
Mouse models of T-ALL  
 
 Genetic models, bone marrow transplant models, and xenograft models 
exist to model human leukemias in the mouse. The transcription factor TAL1/SCL 
is important in early hematopoiesis and is normally expressed in hematopoietic 
progenitor cells; however, 60% of T-ALL patients exhibit aberrant TAL1 
expression. Mis-expressing TAL1 in developing mouse thymocytes by utilizing the 
LCK promoter leads to lymphoid hyperplasia in 30-33% of mice and lymphoma in 
60-67% of mice44. LMO2 is a key TAL1 binding partner and misexpression of both 
oncogenes under the LCK promoter leads to fully penetrant lymphoid 
malignancy45. A similar SCL/LMO1 mouse model has also been developed for 
studying T-ALL. These mice exhibit an expansion of thymocyte progenitors and 
develop leukemia around 20 weeks46. Overall these mouse models highlight the 
collaborative role of TAL/SCL and LMO proteins in leukemic transformation. 
Importantly, LMO2 is essential for sustaining leukemic tumor growth47. 
 10% of T-ALL patients exhibit activating mutations in RAS. Expression of 
mutant K-rasG12D in developing mouse thymocytes results in spontaneous T-ALL. 
Interestingly, half of the mice develop mutations of Notch148. T-ALL can also be 
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modeled in the mouse through loss-of-function mutations in the tumor suppressor 
PTEN, which are observed in 11-27% of T-ALL patients49. Vav-icre mediated 
deletion of PTEN leads to highly penetrant T-ALL50. 
 Aberrant NOTCH signaling is highly prevalent in patients with T-ALL and 
this pathway has been utilized to create both a transgenic and retroviral ICN1 bone 
marrow transplant mouse model of T-ALL. A doxycycline induced overexpression 
of ICN1 leads to malignant transformation51.  
 While genetic mouse models of T-ALL have led to a vast number of key 
findings, the development of patient derived xenografts for T-ALL allows for 
research in a humanized setting through transplantation of primary patient 
leukemic cells into immunocompromised mice. The lack of mature T and B cells in 
these mice allows the patient cells to expand and infiltrate the bone marrow, spleen 
and peripheral blood of the animals, recapitulating the human disease. These 
models have allowed for pre-clinical testing of new therapeutics and have 
increased our understanding of leukemogenesis and drug resistance in T-ALL 
patients52–54.  
 
ALL- Current Therapies 
 
Treatment for both T and B lineage ALL typically takes place in 3 phases, 
including induction, consolidation and maintenance therapies. Induction therapy 
consists of vincristine, glucocorticoids such as dexamethasone or prednisone, and 
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an anthracycline, such as doxorubicin55. Alternatively, the Hyper-CVAD approach 
is utilized, which includes cyclophosphamide, vincristine, doxorubicin and 
dexamethasone alternated with methotrexate and cytarabine. Intrathecal 
chemotherapy is administered for patients with risk of CNS infilitration56,57. 
Consolidation chemotherapy includes similar agents to induction; however, at this 
point some patients may be eligible for stem cell transplant. Finally, maintenance 
therapy proceeds for 2-3 years and involves daily 6-MP, weekly methotrexate and 
corticosteroid doses every few months55.  
This combination chemotherapy has improved remission rates in ALL to 
over 90%. These therapies have different mechanisms of action. Vincristine 
targets the cells during mitosis causing depolymerization of the microtubules 
leading to metaphase arrest and subsequent apoptosis58. Glucocorticoids induce 
cell death via transcriptional regulation of pro-survival and pro-apoptotic genes59. 
Cyclophosphamides are cytotoxic due to DNA cross-linking60. Finally, 
anthracyclines intercalate between DNA and RNA preventing their synthesis and 
leading to apoptosis61. Utilizing drugs that work via differing mechanisms is 
advantageous, as drug resistance now requires acquisition of resistance to 
multiple pathways. 
ALL therapy is currently being revolutionized by the discovery of Chimeric 
Antigen Receptor (CAR)-T-cells. CAR-T-cells are genetically modified T-cells 
which express an antigen to target tumor cells for T-cell mediated killing. In B-cell 
lineage ALL, CAR-T-cells targeting CD19 have been very effective at inducing 
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remission in both adult and pediatric patients at rates up to 90%62,63. The first CAR-
T studies have involved exclusively T-cells generated from the patient; however, 
an “off-the-shelf” CAR-T therapy involving allogeneic transplant would increase the 
effectiveness and availability of this therapeutic strategy. Studies utilizing this 
method are beginning to enter clinical trials64. While CAR-T-cells are an effective 
addition to ALL treatment, there is still a sub-set of patients that exhibit relapse, 
often due to CD-19 down regulation65. Targeting multiple antigens will help to 
combat this problem. Patients also relapse with CD-19 positive disease, which can 
result from a defect in the cytotoxic nature of the T-cells such as repression of 
TRAIL, CAR-T exhaustion, and an anti-inflammatory micro-environment66. 
Utilizing a CAR-T-cell approach for T-ALL is more challenging. As CAR-Ts 
are typically generated from patients there may be a paucity of normal T cells in T-
ALL patients. Furthermore, an antigen has yet to be identified that would 
specifically kill T-ALL cells but spare normal human T-cells and prevent fratricide. 
However, clinical trials have begun to test the effectiveness of targeting CD5, CD7, 
CD30, and CD4. CAR-T treatment of T-cell malignancy would be more successful 
with allogenic CAR-Ts. CRISPR-CAS9 genome editing technology has been 
utilized to disrupt the endogenous T-cell receptor and B2M gene on T cells to 
create allogenic T-cells which do not cause graft vs. host disease in recipients due 
to these alterations67,68. Overall the CAR-T field is progressing rapidly and 







 While intensified chemotherapy protocols outlined above have increased 
cure rates for T-ALL to above 80%, pediatric patients that are diagnosed with 
relapsed ALL have overall survival rates of only 30%. 71.4% of T-ALL patients 
exhibit a clonal relationship between diagnostic and relapse disease, suggesting 
that relapse clones are present at low levels at diagnosis and maintained during 
initial therapy. These clones then persist through therapy resulting in relapse69. 
Gene expression, copy number, and methylation analyses of paired samples 
reveal some pathways that may contribute to relapse. Notably, these studies find 
that the WNT/B-Catenin pathway is consistently deregulated at relapse. While 
gene expression profiles between relapsed ALL patients are diverse, some genes 
seem to be consistently altered70. One promising target from studies examining 
the relapse gene expression signature is BIRC5 or SURVIVIN, which is 
upregulated in a majority of relapse samples71. The MAPK pathway, and loss of 
CDKN2A/B and IKZF1 have also been implicated in increased relapse risk69,70. 
However, while informative, these sequencing-based studies of paired samples 
have limitations as it is difficult to distinguish between driver and passenger 
mutations and to determine which altered pathways play a key role in relapse.  
 One model of cancer relapse involves a rare population of cells termed 
cancer stem cells. These cells are hypothesized to be drug resistant and persist to 
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re-initiate disease following remission72,73. In ALL, this cell population is termed 
leukemia-initiating cells or L-ICs and characterizing these cells could help to better 
target them and reduce relapse rates. In T-ALL it is thought that thymocyte 
progenitors, defined as DN3 and DN4 cells, exhibit L-IC activity74,75. Limiting 
dilution transplants developed for hematopoietic stem cells allow estimation of the 
frequency of leukemia-initiating cells in a given population76. This also allows 
quantification of leukemia-initiating cells after perturbation of candidate therapeutic 
pathways.  Limiting dilution studies show that L-IC activity relies on NOTCH1 and 
MYC signaling, highlighting the potential for therapeutic targeting of this population 
using gamma-secretase inhibitors, which prevent NOTCH signaling, or BRD4 
inhibitors, which limit MYC expression77,78. While these are appealing targeted 
therapies, studies on their clinical efficacy are ongoing. Additional pathways have 
been implicated in L-IC activity, including signaling by Calcineurin/NFAT and 
IGF1R, as repression of these pathways reduces the ability of leukemic cells to 
transplant in mice79,80. L-IC activity may also be regulated by micro-environment, 
as studies show that the CXCL12/CXCR4 chemokine signaling axis is required for 
L-IC activity81. Furthermore, IL7-receptor signaling is essential for L-IC activity and 
can be a marker for cells with L-IC characteristics82.   
Predicting patient prognosis is key to combat relapse in ALL. Response to 
glucocorticoids such as dexamethasone and prednisone is the leading prognostic 
indicator in pediatric ALL83,84. Hongo et al. utlize in vitro drug testing of 16 
compounds to better understand contributions of drug resistance to relapse and 
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induction failure. Patient cells that exhibited resistance to dexamethasone, 
prednisolone, asparaginase and vincristine had an average event free survival rate 
of 54%, while the sensitive group was 83%83. The Berlin-Frankfurt-Munster group 
treat patients for 7 days with the glucocorticoid prednisone alone. These studies 
highlight the in vivo significance of patient glucocorticoid response. In a study with 
high risk infant ALL patients, patient leukemic blast count at day 0 and day 7 of 
prednisone treatment is recorded and patients are characterized as prednisone 
good responders or prednisone poor responders. Good responders had an event 
free survival rate of 53% and poor responders has an event free survival rate of 




 Glucocorticoids, naturally produced by the mammalian adrenal gland, 
regulate several biological pathways. Their ability to cause cell cycle arrest and 
cytotoxicity in certain cell types has led to the use of synthetically derived 
glucocorticoids as chemotherapeutic agents for lymphoid malignancies85. 
Synthetic glucocorticoids include dexamethasone and prednisone, and studies 
have shown that dexamethasone leads to improved overall survival, but also is 
associated with more adverse effects86. Glucocorticoids enter the cell through 
simple diffusion87. Once in the cells, glucocorticoids bind to cytosolic glucocorticoid 
receptors (GR) which facilitate to induce gene expression changes. The effects of 
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glucocorticoids are almost exclusively mediated through activation of the GR, as 
exemplified by a lack of dexamethasone induced cell death upon GR knockout88. 
 The GR is encoded by the NR3C1 gene and is one of the best characterized 
transcriptional regulatory factors. The GR contains a zinc finger DNA binding 
domain and a ligand binding domain, as well as 2 regulatory regions defined as 
activation function domains 1 and 289. Alternative splicing of the NR3C1 mRNA 
results in 2 major GR isoforms, alpha and beta. The alpha isoform is the most well 
characterized, while the beta isoform has been defined as a dominant negative 
regulator of alpha90. From hereon, information relating to GR refers to GR-alpha 
only. In addition to regulation by alternative splicing, the GR protein can also be 
post-translationally modified through phosphorylation, sumoylation, ubiquitination, 
and acetylation90. The GR has 3 well-defined phosphorylation sites including S203, 
S211 and S226. S203 and S211 positively regulate GR activity where S226 can 
be inhibitory91. Hyperphosphorylation of the GR occurs after ligand binding and 
key kinases include cyclin-dependent kinase 2 (CDK2), mitogen-activated protein 
kinase (MAPK), and glycogen synthase kinase 3 (GSK-3)90,91.  
Unliganded GR is sequestered in the cytoplasm bound by chaperone 
proteins including HSP90, HSP70, and p2392. Upon glucocorticoid binding to GR, 
the protein undergoes a conformational change, dissociating from chaperone 
proteins and exposing the nuclear localization signals, which results in rapid 
translocation into the nucleus. In the nucleus, the GR binds DNA at glucocorticoid-
response-elements (GREs). The GRE sequence is made up of 2 6 base pair half-
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sites, that facilitate GR binding to DNA as a homodimer92. There has been 
extensive research on GR transcription, which has found 3 primary mechanisms 
of gene regulation. First, the GR directly binds DNA at the GRE and recruits co-
activator or co-repressor proteins to alter gene transcription. Co-activator proteins 
associated with GR include SRC1-3, p300 and CARM193. Furthermore, the GR 
interacts with NCOR and SMRT to repress gene transcription94. A second way GR 
can regulate gene transcription is through direct interactions with other DNA-bound 
proteins such as STAT3. Importantly, GR also interacts with the p65 subunit of NF-
kB and c-jun of AP-1 transcription factors. This interaction results in GR 
antagonization of their activity, resulting in the anti-inflammatory effects of 
glucocorticoid signaling92. GR can also regulate gene expression through 
composite DNA binding with other transcription factors, including NFKB see above 
and AP-1, where it represses their signaling by directly binding DNA at composite 
sites and recruiting GRIP1 to inhibit inflammatory gene transcription95. Both DNA 
dependent and independent mechanisms of GR gene regulation are involved in 
several biological processes; however, while a GR knockout mouse is lethal, a 
mouse expressing a GR DNA-binding domain mutant is viable, highlighting the 
importance of GR’s ability to regulate signaling independent of DNA96.  
Consensus site alone is not sufficient to determine GR DNA-binding. In a 
given cell type, GR only occupies a small percentage of potential binding sites, 
which contributes to the cell-type specific gene expression profiles89. GR gene 
regulation also cannot be determined by proximity to a locus, as studies find that 
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the GR mediates gene expression changes through long range chromatin 
interactions often over 10 kb away97. Assays utilizing DNase1 hypersensitivity sites 
reveal that the GR predominantly binds open chromatin, suggesting that the pre-
existing chromatin structure, in addition to specific binding motifs, is key for GR 
binding98. While GR binds open chromatin, chromatin re-modeling still occurs 
following binding to induce gene expression changes. Following GR binding to 
enhancer regions, enhancer activation markers including H3K27Ac increase, 
chromatin accessibility further increases, and cooperating transcription factors are 
recuited99–101.  Following DNA binding, GR interacts with MED1 via its ligand 
binding domain and MED14 through its AF1 domain. Interactions with these 
mediator proteins induce conformational changes which allows recruitment of 
RNA-polymerase II to the mediator complex to induce gene transcription89. 




 Glucocorticoids regulate several pathways depending on the cell type90. In 
lymphoid cells, the GR induces a gene expression signature which results in cell 
death102. Studies find that induction of cell death by glucocorticoids, such as 
dexamethasone, is dependent on GR signaling103. Furthermore, unlike the anti-
inflammatory role of the GR, which relies heavily on protein-protein interactions, 
the pro-apoptotic role of the GR relies, at least partially, on the ability to trans-
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activate gene expression through direct DNA binding. However, conflicting studies 
have been published, which find massive over-expression of GR DNA binding 
mutants can sensitize to glucocorticoid-induced apoptosis96,104. Studies also find 
that auto-induction of the GR itself is essential for cell death following 
glucocorticoid treatment105. In contrast, cells that do not undergo glucocorticoid-
induced apoptosis exhibit a negative feedback loop preventing GR signaling106.  
 Several mechanisms of cell death downstream of glucocorticoid signaling 
have been implicated. Certain pro-apoptotic members of the BCL-2 protein family 
have been implicated in glucocorticoid-induced apoptosis. Most convincingly, 
induction of BIM and PUMA by glucocorticoids plays a role in downstream 
apoptosis. Bcl2l11 (BIM) knockdown or knockout partially rescues response to 
glucocorticoid in vitro and in vivo107,108. Similarly, PUMA-deficient thymocytes are 
resistant to glucocorticoid-induced apoptosis109. Furthermore, a double deficiency 
in the pro-apoptotic proteins Bax and Bak confers thymocyte resistance to 
glucocorticoids110.  These proteins induce cell death by initiating cytochrome c 
release from the mitochondria, which triggers apoptosis by activating caspases111. 
Together, these data suggest a key role for this pathway downstream of 
glucocorticoids. 
 Caspases are also typically involved in cellular apoptosis; however, the role 
for caspases in glucocorticoid-regulated apoptosis is not well defined. Studies 
utilizing the pan-caspase inhibitor z-VAD show that caspase inhibition rescues 
primary thymocytes from glucocorticoid induced apoptosis112. In a comparison of 
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caspase 3, 8 and 9, all 3 family members were induced by dexamethasone 
treatment but only inhibition of caspase 3 and 8 could rescue induction of apoptosis 
in thymocytes112. In vivo findings, utilizing knockout mice, differ from findings using 
pharmacological inhibition. Thymocytes from caspase 9- and APAF-1-deficient 
mice exhibit GC resistance113,114, while caspase 8- and 3-deficient T-cells show no 
difference in glucocorticoid-induced apoptosis115,116. This discrepancy leaves the 
role of caspases 3 and 8 in glucocorticoid-induced apoptosis unclear, but suggests 
that caspase 9 and APAF-1 are key in glucocorticoid signaling.  
 In addition to downstream apoptotic machinery, several genes are 
regulated by glucocorticoids which may play a role in cell death102. One gene 
consistently upregulated in dexamethasone treatment studies is GILZ 
(Glucocorticoid-induced-leucine-zipper)117. GILZ has been implicated in inhibition 
of pro-survival protein BCL-XL and the pro-survival pathway NF-kB118,119. 
Dexamethasone also frequently upregulates IkBa (Nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, alpha), which sequesters p65/p50 
in the cytosol, further suggesting a role for NF-kB inhibition in GR-induced 
apoptosis102. There is also evidence for downregulation of other pro-survival 
pathways including c-myc and IL-685. Overall, both upregulation of pro-apoptotic 
pathways and inhibition of pro-survival pathways may contribute to glucocorticoid 






Glucocorticoids in thymocyte development 
 
 The thymus produces corticosteroids, but whether GC influence thymocyte 
selection are controversial120. Using an anti-sense GR (Nr3c1) mRNA under 
control of the Lck promoter to generate GR-deficient thymocytes finds a reduction 
in DP thymocytes which leads to reduction in mature peripheral T-cells. T-cells 
present in the animal have a reduced diversity in TCR rearrangements121 These 
data suggest that GR signaling is essential for positive selection122 Another study, 
which uses the same mouse model, found increases in DP thymocytes and 
peripheral T-cells, suggesting that GR enhances negative selection. Interestingly, 
these analyses report different levels of GR knockdown, so this could explain the 
phenotypic differences. Animals that are completely deficient for GR die at birth; 
however, 10-20% survive and those adults have normal T-cell development, which 
suggests that when GR is lost there may be compensatory mechanisms that 
prevent differences in thymocyte development123. Conversely, studies using a 
conditional Nr3c1 mouse found a reduction in thymocyte number in experimental 
animals, suggesting a block in differentiation or a sensitivity to TCR-mediated 
deletion, similar to the first studies utilizing the antisense Nr3c1 mRNA121,124. An 
additional finding in the GR DNA binding mutant mouse saw no differences in 
thymocyte differentiation96. The variability in findings regarding GR signaling and 
thymocyte development may be due to differences in knockdown efficiency and 
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time of knockdown; however, more work is required to definitively state the 
contribution of GR signaling to T-cell development.   
 
Dexamethasone resistance mechanisms 
 
 While the role of GR signaling is controversial in normal thymocytes, it is 
well established that it is critical for induction of leukemic cell death. Unfortunately, 
resistance to the glucocorticoids dexamethasone or prednisone is a key clinical 
feature of relapse ALL and an important prognostic factor in the disease. Several 
mechanisms of dexamethasone resistance have been defined. Dexamethasone 
resistance can arise from direct loss-of-function mutations in the GR encoding 
gene NR3C1 or the GR co-activator protein CREBBP125,126. These mutations 
would directly affect GR mediated transcription of target genes; however, these 
occur in less than 10% of patients and account for a minority of dexamethasone 
resistant cases.  
 Other mechanisms of dexamethasone resistance interfere directly with GR 
activity. For example, the AKT1 kinase can phosphorylate the GR at the S134 site. 
This phosphorylation blocks GR-mediated gene expression by preventing nuclear 
transport. Importantly, activation of AKT1 is driven by PTEN loss, a predominant 
tumor suppressor in ALL. Consistently, PTEN loss is associated with primary 
glucocorticoid resistance in patients29,127. Glucocorticoid activity can also be 
affected by degradation of the GR protein. The GR can be enzymatically cleaved 
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by CASP1, which is activated by NLRP3 secretion. This cleavage results in 
resistance to glucocorticoid-induced gene expression and cell death. Consistently, 
CASP1 and NLRP3, members of the NALP3 inflammasome, are upregulated in 
glucocorticoid resistant ALL128. Interestingly, inhibition of NOTCH1 signaling with 
gamma secretase inhibitors (GSIs) can reverse glucocorticoid resistance in ALL, 
suggesting interplay between glucocorticoid signaling and NOTCH1. In fact, the 
NOTCH1 target gene HES1 binds to the GR promoter region interfering with GR 
auto-induction, which is essential for sensitivity to glucocorticoid therapy. However, 
while these data are interesting, GSIs have limited efficacy in patients due to 
severe issues with toxicity105,129. Together these data suggest a direct role for 
activated NOTCH1 in GC resistance. In addition to NOTCH1 and PTEN, another 
gene implicated both in leukemogenesis and glucocorticoid resistance is the tumor 
suppressor IKAROS, encoded by the IKZF1 locus. Loss of function mutations in 
IKZF1 are associated with relapse Ph-negative ALL. Interestingly, studies find that 
down regulation of IKAROS leads to inhibition of glucocorticoid regulated gene 
expression and cell death, which may be explained by a role for IKAROS in 
transcriptional regulation at GRE sites based on IKAROS induction to a GRE 
reporter130. 
In addition to direct effects on the GR protein or GR transcription, several 
mechanisms of GC resistance involve activation of pro-survival pathways including 
IL-7-JAK/STAT, FLT3, LCK, PI3K/mTOR, WNT, and MAPK131–137. Mutations in 
JAK1 and KRAS, which both encode components of the IL7-receptor signaling 
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pathway, are associated with steroid resistance in T-ALL132. Additionally, IL-7 
induces steroid resistance and this can be reversed using JAK/STAT pathway 
inhibitors131. Another cytokine that may contribute to glucocorticoid resistance is 
IL-4, as IL-4 overexpression is associated with LCK hyperactivation which results 
in glucocorticoid resistance. LCK inhibition can reverse resistance to 
dexamethasone134. A point mutation in FLT3 is also associated with 
dexamethasone resistance and may lead to constitutive receptor tyrosine kinase 
signaling. Importantly, RTK inhibitors could restore dexamethasone sensitivity in a 
human B-ALL cell line133.  MTOR, WNT and MAPK inhibitors have also been 
shown to synergize with glucocorticoid treatment135–137; however, these agents 
have yet to enter the clinic as GC-sensitizing agents.  
A key advance in the glucocorticoid resistance field was published by Jing 
et al. in 2018138. They find that glucocorticoid resistant ALL differs in chromatin 
accessibility at GR bound enhancer regions. Specifically, they observe methylation 
of the GRE at the BCL2L11 enhancer in 5/5 tested resistant ALL samples. 
BCL2L11 encodes the key pro-apoptotic protein BIM and this methylation results 
in a lack of induction of BIM by glucocorticoid treatment in resistant samples. This 
finding suggests epigenetic modifiers as a therapeutic strategy in glucocorticoid 
resistant ALL.  
 




 Nuclear receptors comprise a superfamily of proteins, including steroid 
hormone receptors. cDNA hybridization screening, utilizing the human estrogen 
receptor cDNA, identified a new family of nuclear receptors classified as estrogen 
related receptors139. While these receptors were identified using the estrogen 
receptor, they share only 30-40% homology in their ligand binding domains, and 
thus they do not bind estrogens. Currently no endogenous ligand has been 
identified so the estrogen related receptors are classified as orphan nuclear 
receptors140. While these receptors share 60-70% similarity to the estrogen 
receptor DNA-binding domain, they do not bind the estrogen receptor palindromic 
DNA binding sequence141. The estrogen related receptor (ERR) family includes 
ERRalpha, ERRbeta, and ERRgamma. These proteins are made up of an N-
terminal domain with an activation function domain, a DNA-binding domain and a 
ligand binding domain which contains that activation function 2 (AF-2) domain. The 
AF-2 domain confers transcription factor activity as it allows for recruitment of co-
activator proteins142. These receptors are most similar in their DNA binding 
domains, where they share 91-98% homology. They differ in their ligand binding 
domains which are 62-77% similar, and further differ in their N-terminal domains 
which are only 15-59% similar141. The ERR DNA-binding domain is highly 
conserved between family members and confers binding to the TCAAGGTCA DNA 
sequence, for which both monomeric and dimeric binding has been 
implicated143,144. Unlike other nuclear receptors, the ERRs do not seem to require 
ligand to induce transcriptional changes, and this has been attributed to its basal 
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ligand binding domain conformation, which supports the recruitment of co-activator 
proteins  in the absence of ligand 145. Specifically, bulky side chains within the 
ligand binding domain of the ERRs seem to mimic a ligand bound state allowing 
for constitutive activity146. Several co-activator proteins have been associated with 
the ERRs including the steroid receptor co-activators (SRC) and peroxisome 
proliferator-activated receptor co-activators (PGC)145,147. ERRs also interact with 
PNRC2, TLE1, SHP, and RIP140 to regulate transcriptional changes148–150. 
Interaction with these proteins allows ERRs to regulate several biological 
pathways. 
 Analysis of the knockout mouse for each ERR family member reveals their 
role in diverse biological processes. ERRalpha null mice are viable but exhibit 
metabolic deficiencies resulting in reduced weight and fat deposits151. Specifically, 
these mice show gene expression changes in OXPHOS and lipid metabolism 
pathways152. Mice lacking ERRbeta are not viable and their embryos show severe 
placental defects due to defects in trophoblast stem cells highlighting the 
importance of this isoform in development153. Consistent with these findings, 
treatment of  female mice with the ERRbeta antagonist diethylstilbestrol (DES) 
results in defects in placental development154. ERRgamma is also essential for 






 The beta family member of the ERR family of orphan nuclear receptors is 
encoded by the ESRRB gene (Estrogen related receptor beta). While several 
studies focus on ERR gamma and alpha, there has been less research on the 
function of ESRRB 156. This may be in part because it was originally thought that 
ESRRB was only expressed in the heart, kidney and liver. Further characterization 
of ESRRB revealed 2 novel splice isoforms, including short-form ESRRB which is 
ubiquitously expressed and is homologous to mouse ESRRB. Short form ESRRB 
mRNA lacks exons 1,2, 10-12. This study also revealed a third ESRRB isoform 
which lacks exons 1,2, and 10. The full length ESRRB splice variant and the exon 
10 deleted variant have tissue specific expression mainly in the kidney and 
testis157. While all 3 variants contain a nuclear localization signal only short form 
and exon 10 deleted variants localize predominantly in the nucleus. The full length 
variant which contains an F domain is mostly expressed in the cytoplasm, 
suggesting the F domain may inhibit the nuclear localization signal157. The different 
ESRRB isoforms are summarized in Figure 1.4. 
 
ESRRB in development 
 
 As mentioned previously, studies with ESRRB-deficient mice and mice 
treated with the ESRRB antagonist DES reveal a requirement for ESRRB in normal 
placental development153,154. Furthermore, ESRRB was also implicated in chorion 
development during embryogenesis158. While early studies of ESRRB, implicated 
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it only in development of extra embryonic tissues, its expression was also detected 
in embryonic tissues and is important in primordial germ cell development159. 
Importantly this role in embryonic development may be specific to mouse, as 
expression of ESRRB is not detected in human embryos160.  
 ESRRB also plays a role in inner ear development, which does translate 
from mouse to human. ESRRB is expressed in strial marginal cells in the mouse 
inner ear. Using conditional knockout mice, ESRRB was found to be essential for 
proper ear development and homeostasis, as ESRRB loss in the ear what specific 
structure results in hearing impairment and balance issues161. These findings in 
mice are consistent with mutations identified in humans, which lead to dysfunction 
of the ESRRB protein and subsequent non-syndromic hearing impairment 
(DFNB35)162,163.  
 ESRRB expression may also be essential in retina development. ESRRB is 
expressed in rod photoreceptor cells and aged ESRRB deficient mice have 
decreased numbers of photoreceptors164. Mechanistically this role is thought to be 
due to direct regulation by ESRRB of genes associated with rod development164.  
While ESRRB is detected in the human retina, its role in rod cell development is 
unclear165.   
 In addition to its role in development, ESRRB may also be important in 
metabolic pathways, which is consistent with defined roles for ESRRA and 
ESRRG152,155. ESRRB deletion in the hindbrain results in issues with energy 
homeostasis and insulin sensitivity resulting in low weight animals and a lack of 
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satiety. This finding can be at least partially attributed to a decrease in 
neuropeptide Y (NPY) expression, which is important in appetite and weight 
control166.  
 
ESRRB in cancer 
 
 ESRRB has been associated with cancers derived from multiple lineages. 
In prostate cancer, ESRRB is down regulated and expression of ESRRB can 
suppress the growth of prostate cancer cells, possibly through regulation of the 
p21 tumor suppressor167. The ability of ESRRB to influence ERalpha activity 
suggests a role for ESRRB in breast and uterine cancer168. ESRRB may suppress 
growth of breast cancer cells, similar to its role in prostate cancer, but more work 
is necessary to definitively address this question169. ESRRB is frequently deleted 
in glioblastoma and these patients have a significantly worse prognosis compared 
to all other patients. In contrast, those with amplified ESRRB exhibit significantly 
better outcomes156. Overall studies in several cancer types suggest a tumor 
suppressor-like role for ESRRB, but further mechanistic studies are needed.  
 In ALL, ESRRB has been identified as a rearrangement partner for PAX5, 
which regulates B-cell development and transformation170,171. However, this fusion 
gene lacks the full ESRRB DNA binding domain, which is characteristically how 
ESRRB regulates gene expression in cancer167,172. Patients with PAX5-ESRRB 
fusions exhibit a distinctly hypomethylated gene expression signature leading to 
 30 
 
upregulation of oncogenic pathways172. These data contrast the potential tumor 
suppressor role in other cancer types and these differences are most likely due to 
different biological functions of the fusion protein and the normal protein.  
 
ESRRB in pluripotency 
 
 ESRRB is best characterized as an essential pluripotency factor173. Using 
RNA-interference ESRRB was identified as critical for maintenance of mouse 
embryonic stem cell (ESC) self-renewal and ESRRB loss leads to ES cell 
differentiation174 It was then found that ESRRB directly regulates OCT-4 
transcription, another critical pluripotency gene, through a binding site in the 
Pou5f1 (OCT-4) promoter. This promoter was in close proximity to the NANOG 
binding site, which is central to ESC self-renewal175,176.  
The relationship between NANOG and ESRRB has been further dissected. 
Esrrb is the strongest induced NANOG target gene and ESRRB can maintain stem 
cell self-renewal in the absence of NANOG, indicating its critical role in this 
process177. NANOG and ESRRB have also been shown to interact through their 
DNA binding domains to regulate target gene expression176. Downstream of 
NANOG-mediated gene induction, ESRRB maintains pluripotency through 
regulation of gene expression, which is mediated by DNA-binding and recruitment 
of the co-activator NCOA3 through its ligand binding domain178. ESRRB target 
genes have been identified through ChIP-sequencing studies and genes essential 
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for self-renewal are regulated synergistically by the key pluripotency factors 
including ESRRB, NANOG, OCT-4, SOX2, and KLF4175. Importantly ES cell self-
renewal seems to be regulated by a positive feedback loop as ESRRB also 
interacts with OCT-4 to induce NANOG expression, which is essential to 
pluripotency179,180. Furthermore, ESRRB motifs are often located 2-8 base pairs 
away from a SOX2 binding site, indicating that ESRRB also cooperates with SOX2 
to regulate expression of target genes181. In addition to its function as a 
transcription factor is ESCs, ESRRB has also been defined as a mitotic 
bookmarking factor182. While most factors are removed from the DNA during 
mitosis, highly proliferative cells like ES cells require mitotic bookmarking to 
maintain expression of key target genes. ESRRB was found bound to ES-cell 
specific enhancers during mitosis to induce rapid upregulation of Klf4, Tfcp2l1, and 
Tbx3182, further supporting its role in the maintenance of this cell type.  
As ESRRB is essential for ESC pluripotency, it is key to understand how its 
expression and activity are regulated. Interestingly, ESRRB seems to be a target 
of the GSK3/TCF signaling axis, where active GSK3b (glycogen synthase kinase 
3 beta) allows for TCF3-mediated repression of ESRRB183. Therefore, GSK3b 
inhibition prevents TCF3-mediated gene repression and activation of ESRRB. In 
trophoblast stem cells, ESRRB is regulated by FGF signaling, which activates 
ESRRB and induces a distinct cell-type specific gene expression signature through 
interactions with LSD1 and the RNA Pol II integrator complex184. Finally, O-
GlcNAcylation of ESRRB by O-GlcNac transferase at serine 25 has been deemed 
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essential for ESRRB stability, transcriptional activity and interactions with OCT-4 
and NANOG, highlighting the important of post-translational modifications in the 
regulation of these proteins185.  
As ESRRB is a clear regulator of stem cell pluripotency and self-renewal 
studies tested whether ESRRB could function to reprogram differentiated cells into 
immature progenitors. While typically mouse embryonic fibroblasts are re-
programed to induced-pluripotent stem-cells (iPS cells) using c-Myc, Oct-4, Klf4, 
and Sox2 (OSKM factors)186, data show that expression of Esrrb, Sox2, and Oct-
4 is sufficient for stem-cell reprogramming187.  ESRRB’s ability to robustly 
reprogram cells can be attributed to its regulation of cellular metabolism and ability 
to facilitate expression of genes which mediate glycolysis and OXPHOS, which is 
associated with reprogramming188. ESRRB also functions as a pioneer factor189. 
In mouse embryonic fibroblasts, ESRRB can bind to silenced enhancers 
containing high degrees of methylation and closed nucleosomes. This binding 
results in local remodeling of the chromatin, which allows for recruitment of the 
other key pluripotency factors (OCT-4, SOX2, NANOG)189.  
 
ESRRB agonist and antagonist identification 
 
 With interesting roles in cancer and embryonic stem cell biology, there is an 
interest to target ESRRB therapeutically. As mentioned previously DES was 
identified as an ESRRB antagonist, which is detrimental to trophoblast stem cell 
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differentiation in pregnant mice154. 4-hydroxytamoxifen is also an ESRRB 
antagonist; however, its effects are much more potent on ESRRG190. Agonists to 
ESRRB have also been identified. Specifically, 2 very similar acyl hydrazones 
GSK4716 and DY131 (GSK9089) act as specific agonists to the estrogen related 
receptor beta and gamma. Both compounds increase the transcriptional activity of 
these receptors in reporter-based assays, without effecting ESRRA191,192. Insights 
into how these agonists regulate ESRRB and ESRRG, came with identification of 
the crystal structure of ESRRG complexed with GSK4716, which showed binding 
of the agonist to a pocket outside with ligand binding domain. This binding results 
in a slight shift if protein structure which increases with size and stability of the 
ligand binding domain, which facilitates co-activator recruitment for 
ESRRB/G178,193. So far studies have utilized these compounds to target ESRRB in 
cancer, where they inhibit human prostate and breast cancer cell line 
proliferation167,194. This suggests that ESRRB may be a promising therapeutic 
target in other cancer subtypes.  
 
Estrogen related receptors and glucocorticoids 
 
Little is known about a connection between estrogen related receptors and 
glucocorticoids. However, 2 studies find contradictory data. Utilizing CV-1 cells 
expressing a reporter gene and transfection of GR and ESRRB, one study finds 
that ESRRB represses GR activity195. In contrast, a study of the ESRRB/G agonist 
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GSK4716 in skeletal muscle cells found that the agonist increased expression of 
the glucocorticoid receptor and decreased expression of ESRRG to inhibit GR 
transcription196. Our work in chapter 3 will argue for a synergistic relationship 
between ESRRB and GR, similar to the work published on ESRRB and GR in 
muscle cells.  
 
The SOX protein family 
 
 SOX proteins are another family of DNA-binding factors, which have been 
implicated in various stages of development and disease. All of the SOX 
transcription factors contain a high mobility group (HMG) DNA binding domain, 
which has at least 50% homology to the testis-determining factor SRY as well as 
a transactivation domain which confers transcription factor activity197. Utilizing 
sequence and biological function, the SOX transcription factors can be grouped 
into 10 families198. SOX proteins can activate or repress gene expression to 
regulate diverse biological pathways, including WNT signaling, neuron and 
oligodendrocyte development197.  
 
SOX2 in development 
 
 SOX2 is one of the best researched members of the SOX transcription 
factor family that has important implications in stem cell biology and cancer. It is a 
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member of the B group of SOX proteins, with similarity to SOX1,3,14 and 21197. 
SOX2’s critical role in development was first uncovered with studies using the 
SOX2 knockout mouse. SOX2 deletion in the zygote results in early death of the 
embryo, as they fail to develop to the epiblast stage199. Consistent with this finding, 
SOX2 is also required for maintenance of ES cell pluripotency in vitro, due to is 
role in regulating Oct3/4 expression and synergistic activation of pluripotent genes 
and repression of differentiation genes by binding DNA with OCT-4 at OCT-SOX 
motifs200. SOX2 also synergistically regulates gene expression with ESRRB by 
binding ESRRB-SOX motifs181. Interestingly, both knockdown and increase in 
Sox2 expression can cause differentiation of ES cells in vitro, highlighting that 
levels of this protein must be carefully maintained201. SOX2’s ability to maintain ES 
cells led to its inclusion as one of the original reprogramming factors for generating 
induced pluripotent stem cells, where it binds and activates pluripotency related 
genes to induce this lineage change186.  
 Following its role in embryonic development, SOX2 is also critical for the 
development of various tissues and is important in maintaining homeostasis in 
adult issues202. SOX2 is key for neuronal development, as it induces neuronal cell 
differentiation203. Furthermore, SOX2 maintains neural progenitor cell identity 
through repression of differentiation genes by binding with co-repressor groucho 
proteins204,205. Deletion of SOX2 in the brain or neural stem cells leads to 
neurodegeneration and hippocampus defects, which can be at least partially 
attributed to SOX2 regulation of the sonic hedgehog pathway (Shh)206,207. These 
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findings can be translated to humans where patients that exhibit mutations in 
SOX2 have hippocampal and eye defects attributed to anophthalmia-esophageal-
genital (AEG) syndrome208–210.  
 In addition to neuronal development, SOX2 has also been associated with 
the gastrointestinal tract. SOX2 is expressed in the developing stomach and 
esophagus and expression of hypomorphic SOX2 alleles result in severe 
impairment of gut development211. Similarly, humans with mutant SOX2 exhibit 
trachea-esophogeal fistula210. SOX2 has also been implicated in development of 
teeth, trachea, retina, hair follicles and the pituitary gland212–216.  
Importantly, SOX2 also plays a key role in the adult stem cells. SOX2 
positive cells are found in several adult tissues including the testes and stomach. 
Lineage tracing of these cells reveals that SOX2 marks adult stem cells which are 
multipotent and self-renewing. These cells give rise to mature cells when needed 
allowing for tissue regeneration. Deletion of these cells results in death of the 
animal217. Overall SOX2 is a critical transcription factors which collaborates with 








 Several studies have found amplifications of the SOX2 locus, including 
samples from lung cancer, glioma and squamous cell carcinoma218–220. SOX2 has 
been implicated in promoting several hallmarks of cancer, including increases in 
proliferation, invasion, and cell survival. Studies in melanoma, breast, prostate and 
ovarian cancer highlight the oncogenic nature of SOX2 and provide evidence that 
downregulation of this protein would be an effective therapeutic strategy. 
Mechanistically, SOX2 can drive pro-proliferative and anti-apoptotic gene 
expression in these malignancies, including p27, p21, Cyclin D, ORAI1 and 
others221–224.  
 SOX2’s role in regulating embryonic stem cell self-renewal and cancer, 
suggests the possibility that SOX2 may regulate cancer stem cells, a population 
thought to mediate cancer recurrence/relapse and drug resistance. Studies in 
prostate, gastric and lung cancers have shown that SOX2 is critical for maintaining 
self-renewal of populations identified as cancer stem cells or cancer-stem-cell-
like225–227.  
 Data suggest that SOX2 may have lineage specific roles. It seems SOX2 
function may be highly cell-type specific, as in some cancers high SOX2 
expression is associated with poor prognosis and in others it is associated with 
good prognosis228. Furthermore, studies which attempt to overexpress SOX2 to 
assess its oncogenic role have found conflicting results. Studies in prostate and 
breast cancer show increased oncogenicity upon SOX2 overexpression223,229. In 
contrast, studies in pancreatic cancer and lung adenocarcinoma find growth arrest 
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following SOX2 overexpression230,231. These differences may reflect cell type 
specific roles for SOX2, but also differences in experimental design. Different 
findings in SOX2 overexpression may be attributed to whether the protein was 
stably or inducibly over-expressed and at what point in transformation 
overexpression occurs228.  Overall it seems SOX2 expression levels must be 
carefully controlled, similar to findings in ES cells where both overexpression and 
repression of SOX2 can initiate differentiation201. This finding is consistent with 
those in pancreatic cancer where both knockdown and overexpression of SOX2 
lead to growth inhibition of the cells230.  
As SOX2 levels need to be carefully controlled, it is critical to understand 
how expression of this protein is regulated. In addition to regulation at the promoter 
region, 2 enhancer regions have been defined for SOX2, which in ES cells can be 
bound by OCT-3/4 proteins232. Interestingly, several microRNAs have been 
reported to regulate SOX2 levels228. For example, miRNA-145 regulates SOX2 in 
human ES cells and miRNA-200c regulates SOX2 in colorectal cancer233,234. A 
long non-coding RNA called SOX2-overlapping transcript or SOX2OT has also 
been identified as a potential regulator of SOX2 expression. SOX2OT 
overexpression or knockdown modulates SOX2 expression; however, the 
mechanistic connection between these 2 is still unknown235. Lastly, SOX2 is 
regulated by several post-translational modifications including phosphorylation by 







SOX2 and PI3K/AKT and WNT 
 
As SOX2 plays a key role in cancer, it is important to decipher which 
pathways it regulates. SOX2 functions seem to be highly interconnected with the 
PI3K/AKT pathway239. This is consistent with the PI3K/AKT pathway being 
essential in cancer cell survival and proliferation240. In breast cancer, AKT 
mediated phosphorylation of SOX2 drives protein stability and subsequent effects 
on oncogenicity241. Furthermore, AKT pathway inhibition reduces SOX2 levels in 
esophageal cancer242. A positive feedback loop seems to exist between SOX2 and 
the PI3K/AKT pathway, as in gliomas and nasopharyngeal carcinoma cells SOX2 
directly activates PI3KCA, which activates AKT signaling243,244. Importantly, SOX2 
was also shown to repress the AKT/mTOR signaling axis in colorectal 
adenocarcinoma cells, again emphasizing that cell type dependent roles of SOX2 
224. 
 SOX family proteins are also often connected to the WNT signaling 
pathway245. In contrast to the activating role SOX2 plays in AKT signaling, multiple 
studies have shown that SOX2 represses WNT signaling. In osteoblasts, SOX2 is 
activated by FGF signaling and constitutive activation of SOX2 blocks osteoblast 
differentiation by inhibiting WNT signaling. Mechanistically, this is due to a direct 
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interaction between SOX2 and B-Catenin which prevents B-catenin from activating 
target genes246. Similar studies were completed in human lung cancer cells, where 
SOX2 also represses WNT/B-catenin signaling; however, the mechanism remains 
unclear247. 
Summary 
 While complete remission rates for T-ALL have increased in the last 
decade, the prognosis for relapse patients remains poor. Response to 
glucocorticoid therapy continues to be used as a prognostic indicator in ALL; 
however, an increased understanding of glucocorticoid resistance mechanisms 
and development of glucocorticoid sensitizing agents would greatly benefit relapse 
and induction failure patients. The goals of my thesis work are to establish novel 
mechanisms of glucocorticoid resistance and utilize those findings to attempt to 






















Figure 1.1 Overview of mouse thymocyte development. Thymic seeding 
progenitor cells (TSP) arrive in the thymic cortex from the bone marrow, in part 
due to signaling through chemokine receptors CCR9 and CCR7. These cells 
then become committed to the T-cell lineage through  NOTCH1 signaling, which 
represses B-cell development. TSPs progress to the DN2a (double negative 2a) 
stage of development where they do not express CD4 and CD8 cell surface 
proteins but do express CD44 and CD25. This progression is controlled by 
various transcription factors including, TCF-1, HEB, BCL11B, NFAT, GATA3, and 
HES1. Stromal signals from delta-like 4 (dll4), sonic hedgehog (Shh), WNT and 
IL-7 are also important in this stage. After DN2b, the cells progress to the DN3 
stage where the T-cell receptor beta rearranges and cells lose CD44 expression. 
HEB, BCL11B, GATA3 and HES1 are critical in transitioning from DN3 to DN4 
stage where cells lose CD25 expression. Through Shh stromal signals and 
TCF-1 gene regulation the DN4 cells transition to double positive (DP) 
thymocytes where CD4 and CD8 cell surface proteins are now expressed and 
the T-cell receptor alpha under goes gene rearrangement. At this point cells are 
NOTCH1 independent. DP cells then under go positive and negative selection in 
the thymic medulla to become mature CD4 only or CD8 only T-cells.ThPOK, TOX 
and GATA3 signaling result in the CD4 lineage and RUNX3 and NOTCH1 
regulation leads to the CD8 lineage. IL-7 signaling is important in this stage. 
Adapted from Shah, D. K. & Zúñiga-Pflücker, J. C. An Overview of the 
Intrathymic Intricacies of T Cell Development. The Journal of Immunology 192, 
4017–4023 (2014).
















































Figure 1.2 Overview of T-ALL oncogenes and tumor suppressors. Thymocyte 
transformation can occur at the ETP, early cortical and late cortical stage of 
thymocyte differentiation, with various oncogenes contributing to leukemia. 
Mutations in NOTCH1 and loss of the CDKN2A tumor suppressor are the most 
prevalent genetic aberrations in this malignancy. Activation of the homeobox 
genes TLX1 and TLX3 are typically seen in early cortical T-ALL where as 
TAL1/LMO activation is common in late cortical T-ALL. Activation of these 
oncogenes prevents normal differentiation to mature T-cells. Following 
differentiation arrest leukemic proliferation is driven by MYC, AKT, and JAK-STAT 
signaling. Adapted from Belver and Ferrando.The genetics and mechanisms of T 







Mutations in NOTCH1 (65% of patients) and FBXW7 (20% of patients)











Figure 1.3 Glucocorticoid Signaling Overview. Glucocorticoids enter the cell 
by simple diffusion where they bind glucocorticoid receptors (GR). Ligand binding 
allows GR to dissociate from chaperone proteins, become phosphorylated and 
enter the nucleus. In the nucleus the GR can regulate gene transcription in a 
positive and negative manner by binding glucocorticoid response elements 
(GRE). It can also tether to DNA via STAT3 and NfKb. Furthermore it can bind in 
a composite manner with other transcription factors such as STAT5 and c-jun/fos 
AP-1 proteins. Adapted from Liu, Zhang, Knight & Goodwin. The Glucocorticoid 
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Figure 1.4 Human ESRRB isoforms. Alternative splicing of the human ESRRB 
mRNA generates 3 different isoforms. The full length form ESRRB2 contains 12 
exons and the F domain of ESRRB2 limits nuclear localization. ESRRB2delta10 
does not contain exon 1 or 10. Deletion of exon 10 alters the F domain allowing 
nuclear accumulation of this isoform. Short form ESRRB only contains exons 2-9 
and is homologous to mouse ESRRB. This isoform does not contain the F 
domain and localizes to the nucleus. Adapted from: Zhou, W. et al. Identification 
and characterization of two novel splicing isoforms of human estrogen-related 
receptor beta. J Clin Endocrinol Metab. 2006 Feb;91(2):569-79 
1 2 3 4 5 6 7 8 9 10 11 12
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ESRRB regulates glucocorticoid gene 
expression in mice and patients with 
acute lymphoblastic leukemia 
 
Data from the following chapter were part of a published paper: 
Gallagher KM, et al. ESRRB regulates glucocorticoid gene expression in 
mice and patients with acute lymphoblastic leukemia. Blood Advances 
(2020) 4 (13): 3154–3168. 
All figures were generated by Kayleigh Gallagher with contributions from Justine 
Roderick (Figures 2.1, 2.11), Shi Hao Tan and Tze King Tan (Figures 2.6, 2.7. 







Glucocorticoids are critical components of multi-agent chemotherapy for 
lymphoid malignancies. Of the lymphoid malignancies, ALL is the most common 
malignancy of childhood and involves transformation of B- or T- lymphoid 
progenitors248,249. A patient’s response to glucocorticoids (GC) is the most reliable 
prognostic indicator in pediatric ALL and GC resistance remains an obstacle to 
improving outcomes for these patients83,84. In lymphoid cells, synthetic GCs such 
as dexamethasone induce apoptosis by stimulating glucocorticoid-receptor (GR) 
translocation to regulate transcription250. In lymphoid cells, GC treatment induces 
pro-apoptotic genes including BCL2L11 (BIM).  There is also evidence that the GR 
represses expression of the pro-survival genes BCL2 and BCL-XL251. 
 GC resistance can result from mutation in NR3C1, encoding the GR, 
however these mutations are rare in relapsed ALL126. GR activity can also be 
impaired due to AKT-mediated phosphorylation of the GR or NLRP3 
inflammasome activation and caspase 1-mediated cleavage of the GR127,128. 
Impaired GC responses can also result from missense mutations in NR3C1 
coactivators such as CREBBP125. Several mechanisms of GC resistance involve 
activation of pro-survival pathways including LCK, FLT3, WNT, MAPK, IL-7-
JAK/STAT or mTOR signaling131–134,136,137. An impaired GC response in ALL can 
also reflect increased DNA methylation of BCL2L11 locus observed in a subset of 
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GC resistant patients138. Lastly, mutations in NOTCH1 increase HES1 levels which 
interfere with GR autoregulation, contributing to GC resistance129.  
 To further elucidate GC resistance mechanisms in ALL, we performed an 
shRNA screen in primary T-ALL cells isolated from a Tal1/Lmo2 mouse T-ALL 
model45.  We found shRNAs targeting the GR (Nr3c1) or known GC resistance 
genes (Rcan1, Mllt10, Smarca1, Smard2, Btg1) enriched in the screen. 
Importantly, shRNAs for Ikzf1, Utx and the CREBBP paralog Ep300, known 
leukemia suppressor genes in human ALL, conferred dexamethasone resistance 
in our mouse screen. Our screen did not identify negative regulators of NOTCH1 
signaling as mechanisms of GC resistance; however, this may be due to the 
requirement of multiple hits in this pathway or because NOTCH is already active 
in these cells. An shRNA targeting the Estrogen Related Receptor Beta (ESRRB) 
was identified in the screen. ESRRB is a member of the Estrogen Related 
Receptor (ERR) family of orphan nuclear receptors and known to act as a 
constitutively active transcription factor that binds an estrogen related response 
element (ERRE) to regulate gene expression141. ESRRB has been studied in 
mouse embryonic stem (ES) cells, where ESRRB maintains self-renewal through 
activation of Oct-4 and as a member of the NANOG complex176,177. We reveal 
novel functions for ESRRB in the control of GR-mediated transcription and show 
that an ESRRB agonist potentiates dexamethasone-induced gene expression and 
apoptosis. These data suggest that ESRRB agonists may provide therapeutic 





The orphan nuclear receptor ESRRB regulates glucocorticoid-induced cell 
death in vitro and in vivo. 
 
To identify GC resistance genes, we transduced the dexamethasone-
sensitive mouse T-ALL cell line 1390 with a whole genome lentiviral TRC (The RNAi 
Consortium) library, containing ~75,000 shRNA constructs directed against 16,000 
genes. Leukemic cells were infected with a MOI of 0.2 to achieve a single shRNA 
per cell. Infected cells were selected with puromycin for 48 hours and treated with 
dexamethasone for 4 days to kill >99% of the leukemic cells. Surviving cells were 
expanded and sequenced to identify shRNAs that confer dexamethasone resistance 
(Figure 2.1A). This screen identified an shRNA specific for ESRRB, an orphan 
nuclear receptor containing a zinc-finger DNA binding domain and a ligand binding 
domain which contains an activation function (AF) 2 domain for the recruitment of 
co-activators or co-repressors178 (Figure 2.1B). We achieved >50% knockdown of 
Esrrb in mouse T-ALL cells using 2 independent shRNAs (Figure 2.1C; Figure 
2.2A). To determine whether ESRRB alters dexamethasone response, we treated 
leukemic cells deficient for Esrrb or Nr3c1 encoding the GR, with dexamethasone 
and assessed cell viability by MTS assay and cell death by Annexin V/7-AAD 
staining. Knockdown of Esrrb prevents dexamethasone-induced cell death and 
shifts the GI50 for dexamethasone approximately 96-fold from 6 nM to 564 nM or 
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17-fold when a second, less effective, Esrrb shRNA is used (Figure 2.1D,E). We 
examined GC responses in an additional mouse T-ALL cell line (5059) and found 
that Esrrb knockdown shifts the GI50 from 8 nM to 70 nM and prevents 
dexamethasone-induced apoptosis (Figure 2.1F,G). While we show that an 
ESRRB-deficiency results in dexamethasone resistance in vitro, we recognize that 
dexamethasone resistance in vivo may be influenced by pro-survival factors. For 
example, the lymphoid survival factor IL-7 can contribute to dexamethasone 
resistance132. Therefore, we examined the effects of Esrrb knockdown on the 
dexamethasone response in vivo. Mouse T-ALL cells deficient for Esrrb or Nr3c1 
were transplanted into sub-lethally irradiated syngeneic recipients and treated with 
vehicle or dexamethasone (15 mg/kg) for 3 weeks (Figure 2.1H). In mice 
transplanted with leukemic cells expressing a NS control, dexamethasone 
significantly prolonged survival and eliminated disease in 4/10 mice (Figure 2.1I). 
In contrast, dexamethasone treatment had no significant effect on the survival of 
mice transplanted with Esrrb- or Nr3c1-deficient leukemic cells, where all animals 
succumbed to disease (Figure 2.1J,K). These data demonstrate that an ESRRB-







ESRRB has no effect on the leukemic gene expression signature or on 
leukemic growth.  
 
ESRRB is required for embryonic stem (ES) cell pluripotency and self-
renewal of trophoblast stem cells156. Moreover, ESRRB functions as a mitotic 
bookmarking factor in ES cells182. These findings suggest that ESRRB may alter 
leukemic cell proliferation. We examined ESRRB effects on leukemic growth by 
labeling mouse leukemic cells expressing a non-silencing (NS) control or Esrrb-
specific shRNAs with carboxyfluorescein succinimidyl ester (CFSE) and monitored 
proliferation. An ESRRB-deficiency had no significant effect on CFSE loss/dilution 
due to proliferation. Furthermore, similar numbers of leukemic cells were observed 
in cultures expressing NS- or Esrrb-specific shRNAs (Figure 2.2B,C). To examine 
the effects of an ESRRB-deficiency on leukemic gene expression, we performed 
RNA sequencing on NS- and Esrrb knockdown cells and found that Esrrb 
knockdown had no effect on basal leukemic gene expression (Figure 2.2D). To 
assess effects of ESRRB on leukemic growth in vivo, we transplanted mouse 
leukemic cells expressing NS or Esrrb-specific shRNAs into sub-lethally irradiated 
syngeneic recipient mice and monitored disease. Consistent with the gene 
expression studies, an ESRRB-deficiency had no significant effects on leukemic 




ESRRB cooperates with GR to potentiate dexamethasone-induced gene 
expression.  
 
 GCs, such as dexamethasone, induce cell death in lymphoid cells by 
activating GR-mediated transcription250. We hypothesized that an ESRRB-
deficiency may mediate GC resistance by interfering with expression of GR-
regulated genes. We performed RNA-sequencing on vehicle or dexamethasone 
treated mouse leukemic cells expressing NS control, Nr3c1- or Esrrb-specific 
shRNAs. Our RNA-sequencing studies reveal 339 genes of diverse functions 
altered by dexamethasone treatment of T-ALL cells and as expected, gene 
expression was significantly abrogated by Nr3c1 knockdown (Figure 2.3A,B; 
Figure 2.4). Surprisingly, we find that dexamethasone-regulated gene expression 
was also abrogated by Esrrb knockdown, with 66% of dexamethasone-induced 
genes dependent on ESRRB (Figure 2.3A). Gene set enrichment analysis (GSEA) 
revealed that dexamethasone-regulated gene expression was negatively 
correlated with Esrrb- or Nr3c1- knockdown when compared to leukemic cells 
expressing the NS control (Figure 2.3B upper). When analyzing log-fold change 
(LFC) in NS, Esrrb- or Nr3c1- silenced leukemic cells, the greatest induction of 
dexamethasone regulated genes occurs in the NS control leukemic cells, and 
Esrrb knockdown reduces the expression of 143 of 214 dexamethasone-induced 
genes (66%) (Figure 2.3B lower). ESRRB does not seem to significantly regulate 
gene expression independent of dexamethasone treatment, as only 16 genes were 
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significantly altered following ESRRB repression. Importantly, all genes dependent 
on ESRRB expression are also dependent on NR3C1 expression, suggesting a 
cooperation between these 2 receptors and reflecting that ESRRB does not 
mediate gene expression changes independent of GR. These data reveal that like 
a NR3C1-deficiency, Esrrb knockdown interferes with dexamethasone-induced 
gene expression in mouse T-ALL cells.  
To identify the biological processes regulated by the GR and ESRRB, we 
performed gene ontology analysis using DAVID252,253 and found genes enriched 
for cell death. In fact, dexamethasone induces expression of 42 genes related to 
cell death and 26 of these are dependent on ESRRB (Table 2.1). The ESRRB-
dependent pro-apoptotic genes include Tsc22d3 encoding glucocorticoid-induced 
leucine zipper (GILZ) known to trigger thymocyte apoptosis when 
overexpressed118 and the proapoptotic Bcl2l11 gene encoding BIM (Table 2.1). 
Although Bcl2l11 scored just below the 1.5-fold cutoff, real time quantitative PCR 
confirmed Bcl2l11 as well as Tsc22d3 and Nr3c1 expression significantly 
decreased in dexamethasone-treated Esrrb knockdown leukemic cell lines using 
2 independent shRNAs (Figure 2.3C). Additional ESRRB-dependent genes 
include the death-associated protein kinase Stk17b, the Litaf gene implicated in B-
cell apoptosis and the p53 targets Epha2 and Acer2254–257. As induction of pro-
apoptotic BIM is critical for dexamethasone-induced cell death, we confirmed that 
Esrrb knockdown reduces BIM protein levels by approximately two-fold138,258. 
Importantly, we see induction of the short BIM isoform, the most potent inducer of 
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apoptosis, reduced by over 3 fold (Figure 2.3D)259. These data suggest that the 
dexamethasone resistance observed in ESRRB-deficient leukemic cells can be 
explained in part by a failure to induce pro-apoptotic genes and sufficient BIM 
protein levels. 
Our RNA-sequencing data also reveal a set of GC-repressed genes that 
were influenced by ESRRB. Approximately 58% of the dexamethasone-repressed 
genes were affected by Nr3c1 knockdown and 54% of these repressed genes 
appear ESRRB-dependent (Figure 2.5A,B). Consistent with anti-inflammatory 
functions of the GR, we find the repressed genes are related to immune regulation 
(Table 2.2). Interestingly, we find genes important in thymocyte differentiation 
including Myb, Rag1, Rasgrp1 and Runx1 are repressed by dexamethasone in an 
ESRRB-dependent manner. These data are consistent with published B-ALL 
studies, which implicate GC repression of B-cell development genes in the 
therapeutic response260. We validated the repressive effects of ESRRB on three 
randomly selected candidate genes Bcl2l1, Rag1 and Klf3 in mouse leukemic cells 
by real time quantitative PCR and found expression of these genes unaffected by 
dexamethasone in ESRRB knockdown cells (Figure 2.5C). This finding is 
consistent with studies in human ALL cells where dexamethasone represses BCL2 
and BCL2L1251. Because Bcl2l1 (encoding BCL-XL) expression was not 
significantly repressed in ESRRB knockdown cells, we inhibited BCL-XL using the 
ABT-263 inhibitor and found that ABT-263 treatment re-sensitized ESRRB-
deficient cells to dexamethasone-induced apoptosis (Figure 2.5D).  Collectively, 
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these data reveal that ESRRB cooperates with the GR to regulate gene expression 
and is consistent with known functions, where ESRRB recruits co-activators and 
co-repressors to regulate gene expression141.  
 
GBS- and ERRE-containing cis-regulatory elements interact with promoter 
regions of GR- and ESRRB-dependent genes in mouse T-ALL cells.  
 
Our RNA-sequencing data reveal that most dexamethasone-regulated 
genes in mouse T-ALL cells depend on ESRRB. We examined the GR- and 
ESRRB-dependent genes for the presence of estrogen related response elements 
(ERRE). Motif analysis using the ERRE sequence TCAAGGTCA revealed ERREs 
in 49% of these genes with 18% of genes harboring ERREs in promoters, 31% in 
putative enhancer regions and 6% in both promoters and enhancers (Figure 2.6A). 
We then performed H3K27Ac Hi-ChIP in the mouse T-ALL cell line (2553) and 
detected pre-established interactions between putative enhancer regions as well 
as looping between promoter-enhancer elements in the GR/ESRRB-dependent 
genes examined (Figure 2.6B).  Using published GR ChIP-sequencing data261 we 
confirmed GR binding to the promoter and/or enhancer regions of Tsc22d3, 
Camk1d and Sh3rf1 (Figure 2.6B-black arrows). We then validated these findings 
in two additional mouse T-ALL cell lines (720 and 1390) (Figure 2.7).  
ESRRB regulates gene expression in ESCs through complex formation with 
NANOG177, suggesting that an ESRRB/GR complex may regulate GC gene 
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expression. Co-immunoprecipitation experiments however, failed to detect an 
ESRRB/GR complex in ALL cells or in transfected HEK293T cells (Figure 2.8A,B). 
Our analysis of the GR/ESRRB-dependent genes in mouse T-ALL cells found 
GR and ERRE motifs to be non-overlapping (Figure 2.6A), leading us to 
hypothesize that ESRRB and GR bind DNA independently; however, 36% of 
genes harbored sites that were separated by >10kb suggesting that ESRRB and 
GR may interact to mediate chromatin looping. 
 We next examined dexamethasone effects on H3K27Ac levels and 
chromatin looping in human T-ALL cells using canonical GR target genes PIK3IP1, 
FKBP5 and TSC22D3 identified by Piovan et al.127. Similar to our Hi-ChIP studies 
in mouse T-ALL cells (Figure 2.6), we detect pre-existing promoter/enhancer 
interactions in PIK3IP1, TSC22D3 and BCL2L11 (Figure 2.9A,C,D). We utilized 
virtual 4C analysis of our Hi-ChIP data to quantify interaction frequency. Using the 
transcription start site of these GR regulated genes as the viewpoint (red highlight), 
we find that dexamethasone significantly increased the frequency of promoter 
interactions with GR bound and ERRE-containing enhancer elements; 
furthermore, dexamethasone increased H3K27Ac levels at these putative 
enhancers (Figure 2.9A-C). Similarly, we detect increases in active histone marks 
and promoter/enhancer interactions at the BCL2L11 locus, where our Hi-ChIP data 
validate the presence of a dexamethasone-responsive intronic enhancer (Figure 
2.9D), previously observed in GC sensitive ALL cells258.  Together these data 
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suggest that GR and ESRRB binding support these promoter/enhancer 
interactions to potentiate gene expression (Figure 2.9E).  
 
 
Knockdown of ESRRB prevents dexamethasone-induced cell death and 
gene expression in human ALL cells 
 
We then generated ESRRB-deficient human T- and B-ALL cells and 
assayed the dexamethasone response. We validated ESRRB knockdown by 
quantitative real time PCR and by immunoblotting (Figure 2.8C-E). Similar to our 
findings in mouse T-ALL cells, ESRRB knockdown in the human T-ALL cell line 
DND41 shifts the dexamethasone GI50 from 79 nM to 840 nM or 410 nM when a 
second shRNA is used (Figure 2.10A). Like NR3C1 knockdown, both ESRRB 
shRNAs prevent dexamethasone-induced apoptosis of human T-ALL cells and 
interferes with dexamethasone-induction of the GR target genes NR3C1, 
BCL2L11, and TSC22D3 (Figure 2.10B,C). ESRRB knockdown in the human T-
ALL cell line KOPTK1 also prevented dexamethasone-induced gene expression 
and apoptosis (Figure 2.8F,G). Similarly, a deficiency in ESRRB in NALM-6 cells 
shifts the dexamethasone GI50 from 56 nM to 870 nM or 876 nM when a second 
independent ESRRB shRNA is used (Figure 2.10D, Figure 2.8D). ESRRB 
knockdown significantly reduces the percentage of apoptotic leukemic cells and 
interferes with dexamethasone-induced gene expression in NALM-6 cells (Figure 
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2.10E, F). These data suggest that ESRRB may contribute to GC resistance in 
human T- and B-ALL and indicates that although performed in mouse T-ALL cells, 
the genes identified in our screen may be relevant to steroid resistance in other 
lymphoid malignancies. 
Dexamethasone increases ESRRB expression and binding to GR regulated 
genes 
 
The effects of ESRRB repression on dexamethasone-induced gene 
expression suggests that ESRRB cooperates with the GR to induce optimal 
transcriptional responses to dexamethasone. Therefore, we hypothesized that 
dexamethasone may induce ESRRB expression to amplify the GC response. We 
treated human T-ALL cells with dexamethasone for 6 hours and detected 
significant increases in ESRRB protein levels (Figure 2.11A). We analyzed the 
genomic sequence of canonical GC-regulated genes including NR3C1, BCL2L11 
and TSC22D3 and found an ERRE (TCAAGGTCA) in intronic regions of all 3 
genes. We performed chromatin immunoprecipitation-qPCR in the human T-ALL 
cell line KOPTK1 and assayed ESRRB binding to these regions. We detect 
increased ESRRB binding to the ERRE in intron 1 of the NR3C1 gene following 
dexamethasone treatment (Figure 2.11B). These data are consistent with our gene 
expression data and qPCR analyses showing that ESRRB is required for GR 
autoinduction (Figure 2.3C; Figure 2.10C,F).  ESRRB recruitment to the ERRE in 
intron 2 of BCL2L11 and a TSC22D3 enhancer was also observed in human T ALL 
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cells treated with dexamethasone (Figure 2.11C,D). The direct binding of ESRRB 
to dexamethasone-regulated genes in human T-ALL cells further implicates 
ESRRB in GR-mediated transcription. Interestingly, we detect significant ESRRB 
recruitment to BCL2L11 and TSC22D3 in the GC sensitive human T-ALL cell line 
KOPTK1, whereas significantly less ESRRB recruitment to these genes was 
observed in the GC resistant human T-ALL cell line CUTLL1, which also does not 
upregulate ESRRB expression in response to dexamethasone (Figure 2.11B-D; 
Figure 2.12A). Importantly, we do not detect increased ESRRB binding to regions 
of BCL2L11 or TSC22D3 that do not contain an ERRE or exhibit GR binding 
(Figure 2.12B,C)258.These findings are consistent with recent ATAC-seq studies 
that show increased chromatin accessibility in GC regulated genes in GC sensitive 
versus resistant ALL cells138. Taken together these data demonstrate that in 
addition to changes in H3K27 acetylation and promoter-enhancer interactions 
(Figure 2.9), dexamethasone increases ESRRB binding to the ERRE in GC 
sensitive ALL cells and suggest direct regulation of GR target genes by ESRRB. 
 
The ESRRB agonist GSK4716 synergizes with dexamethasone to induce 
human leukemic cell death 
 
The role of ESRRB in the regulation of GR target genes suggests that 
ESRRB expression may be reduced in relapsed ALL samples. We compared 
ESRRB expression in paired ALL samples obtained at diagnosis and upon 
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relapse70. We found ESRRB expression significantly reduced in 24 of 49 ALL 
samples at the time of relapse (Figure 2.13A; p< 0.05) further implicating ESRRB 
in dexamethasone resistance. We did not however, detect evidence of ESRRB 
promoter methylation in relapse patient samples (Figure 2.13B).  We also analyzed 
ESRRB expression in GC sensitive and resistant ALL patient samples and found 
ESRRB significantly reduced in GC resistant samples in one of two data sets 
examined (Figure 2.13C,D)128,258.  We examined additional ALL data sets to 
determine whether ESRRB levels correlate with genetic subtypes of ALL. Although 
no significant differences were detected among B-ALL subtypes (Figure 2.13E), 
ESRRB expression was significantly reduced in TLX1-positive T-ALL samples 
when compared to TAL1-positive samples. Interestingly, TLX1 is a genetic subtype 
associated with steroid resistance (Figure 2.13F)262,263. Although reduced ESRRB 
expression was observed in paired ALL samples at the time of relapse and in GC 
resistant ALL samples (Figure 2.13A,D,F), we confirmed that the ESRRB protein 
is detected in GC resistant (IC50 >1μM) primary T-ALL patient samples (Figure 
2.13G), thereby validating ESRRB as a potential therapeutic target for GC re-
sensitization in relapsed ALL. Finally, we demonstrate that dexamethasone 
significantly increases ESRRB mRNA levels in the human T-ALL cell line KOPTK1 
and in two relapsed T-ALL patient samples examined (Figures 2.13A; Figure 
2.13H). Consistent with these data, dexamethasone increases GR binding to the 
human ESRRB gene in a T-ALL patient sample (Figure 2.13I)258. Collectively, 
these data suggest that ESRRB expression is induced by dexamethasone to 
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feedback and potentiate GR activity and that ESRRB suppression results in GC 
resistance. 
 While ERRs have no known endogenous ligands, synthetic phenolic acyl 
hydrazones increase the activity of these receptors by stabilizing the AF-2 domain 
and increasing co-activator recuitment191. ESRRB- and ESRRG-agonists 
suppress gastric cancer and breast cancer growth in vitro194,264. Initially, we tested 
the effects of the ESRRB/G agonist DY131 on GC responses in human T-ALL cell 
lines. We detect significant increases in dexamethasone-induced apoptosis and 
gene expression when dexamethasone and the ESRRB/G agonist DY131 are 
used in combination (Figure 2.14A,B). The combination therapy resulted in 
significant decreases in the viability of 5 T-ALL patient samples examined, 
including 2 relapsed leukemia samples (TLX-14 and -13) that are resistant to 
dexamethasone (Figure 2.14C). We also examined the effects of a second ESRRB 
agonist GSK4716 and found similar increases in apoptotic leukemic cells upon 
combination treatment (Figure 2.14D). We evaluated agonist selectivity in mouse 
T-ALL cells, where treatment with agonist only induces cell death (Figure 2.14E). 
We demonstrate that GSK4716 and to a lesser extent DY131, induce cell death 
that was dependent on the expression of ESRRB (Figure 2.14E). The 
combinatorial effect of GSK4716 and dexamethasone was evaluated by the 
combination index (CI) method in 2 human T-ALL cell lines (KOPTK1 and DND-
41). This analysis resulted in a CI of <1 indicating that GSK4716 and 
dexamethasone synergize to induce leukemic cell death (Figure 2.14F), providing 
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proof-of-principle that ESRRB activation potentiates dexamethasone-induced cell 




Despite increases in overall survival, relapse remains a critical challenge in 
the care of pediatric ALL patients. Although failure to respond to GCs can predict 
patient outcome83,84, GC re-sensitizing agents have not entered the clinic. Our 
functional screen for GC resistance genes identified ESRRB as a dexamethasone-
inducible transcription factor that cooperates with the GR to maximize the GC-
regulated gene expression signature. We provide evidence that ESRRB directly 
contributes to dexamethasone-induced gene expression in human T-ALL cells 
through direct binding to ERREs in the regulatory regions of the GR target genes 
examined.  
 It is likely that ESRRB cooperates with the GR to regulate gene expression 
through DNA binding followed by co-activator recruitment in leukemic cells, similar 
to findings in ES cells where ESRRB interacts with NCOA3 to mediate gene 
transcription178. The co-activator(s) that function with ESRRB remain unclear; 
however, EP300, NCOA4 and NCOA5 were identified in this screen (Table 2.3), 
suggesting that they may collaborate with ESRRB in leukemic cells. Through 
transcriptome analyses, we establish that ESRRB and GR have overlapping gene 
regulatory functions in the GC response in leukemic cells. However only 66% of 
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the dexamethasone-induced genes depend on ESRRB (Figure 2.3), indicating that 
other TFs remain to be discovered that co-regulate GR transcriptional activity in 
lymphoid cells.  
ESRRB functions as a pioneer factor in the reprogramming of epiblast stem 
cells leading us to speculate that ESRRB may increase chromatin accessibility at 
select GR target genes189. Our Hi-ChIP analysis of GR- and ESRRB-dependent 
genes shows that enhancer elements known to bind the GR in human T-ALL 
cells258 contain ESRRB binding sites and that dexamethasone increases the 
frequency of these enhancer/promoter interactions (Figure 2.9). These data lead 
us to speculate that ESRRB and GR potentiate GC-induced gene expression by 
supporting these chromatin interactions. Our Hi-ChIP data also detect pre-existing 
chromatin interactions at dexamethasone-responsive loci in mouse and human T-
ALL cells (Figures 2.7 and 2.9) indicating that lymphoid cells may be poised for a 
rapid transcriptional GC response. 
 Our work establishes ESRRB repression as a mechanism of GC resistance 
and relapse in ALL.  Treatment of human T- or B-ALL cell lines and samples with 
the ESRRB agonists DY131 or GSK4716 enhanced dexamethasone-induced 
gene expression and cell death. These in vitro data led us to administer DY131 in 
vivo to assess effects on leukemic burden.  Due to the hydrophobic nature of the 
agonist166, issues with agonist solubility prevented assessment of its ability to 
cooperate/synergize with dexamethasone to prevent leukemic growth in vivo. 
Future collaborative efforts will be directed at improving agonist pharmacokinetics. 
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 This work reveals novel functions for ESRRB as a GR regulator. We show 
that ESRRB is a GC responsive gene and is co-enriched along with GR at select 
GC-regulated target genes in human ALL cells. Our study provides mechanistic 
insight into GR transcription and establishes ESRRB as a potential therapeutic 
target to enhance GC action in acute leukemia and potentially other lymphoid 
malignancies.   
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Materials and Methods 
 
Lentiviral production and infection  
HEK-293T cells are plated at 1x106 cells per well in a 6 well tissue culture treated 
plate in DMEM containing 10% FBS. 24 hours later cells are transfected with 
PLKO.1 vector containing NS, Nr3c1 or Esrrb-specific shRNAs (Supplemental 
Table 4) along with packaging plasmids containing gag and pol and envelope 
plasmids in the presence of Effectene (Qiagen). Virus is harvested and filtered 48 
hours post-transfection. Leukemic cells are plated in 12 well plates with polybrene 
(4 μg/ml) and 500 ml virus for 12 hours. Cells are then transferred to 10 cm dishes 
and subjected to puromycin selection 48 hours after infection.  
 
Nuclear Fractionation and immunoblotting To isolate nuclear proteins, 1 X 107 
cells are cultured with DMSO or Dexamethasone and cells were fractionated using 
the Active Motif nuclear extract kit (40010). Leukemic cells are resuspended in 
hypotonic buffer and nuclei isolated and washed 3 times to remove cytoplasmic 
proteins. Nuclear protein was extracted and protein quantified using a Bradford 
assay (Biorad). Protein is run on 8-10% acrylamide SDS gel, transferred to PVDF 
membrane and probed with antibodies to ESRRB (Perseus Proteomics H6705) 
(1:500) or NR3C1 (Cell Signaling D8H2) (1:1000). To ensure equal loading, 





Mice and cells  
Tal1/Lmo2 transgenic mice were monitored for leukemia and mouse and 
human T-ALL cells were cultured as described77. Primary human T-ALL samples 
were expanded in NSG mice and cultured as previously described265. All animal 
procedures used in this study were approved by the University of Massachusetts 
Medical School Institutional Animal Care and Use Committee. 
 
Cell growth/death assays and synergy calculation 
 To quantify apoptosis, cells were treated with increasing concentrations of 
dexamethasone (0-10μM) for 24-72 hours and 2 x 105 cells were resuspended in 
Annexin V staining buffer containing Annexin V-FITC (BD pharmigen) and 7-AAD 
(BD) for 15 minutes and Annexin V and 7-AAD-positive cells quantified by flow 
cytometry. To measure dexamethasone effects on leukemic cell viability, mouse 
or human ALL cell lines or samples were cultured in increasing concentrations of 
dexamethasone for 48 hours and metabolic activity was assayed after 5 days by 
the addition of CellTiter-Glo chemiluminescence reagent (Promega) and 
measured using a Beckman Coulter DTX 880 plate reader. Absorbance values 
were normalized to DMSO control for each patient sample and ALL cell line. 
Nonlinear dose- response curves were fitted, from which the GI50 (the 
concentration of dexamethasone at which 50% of the cells are affected) were 
calculated using GraphPad Prism 5 software (GraphPad).  
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To measure effects on cell viability and growth, cells were counted each day using 
trypan blue stain and a hemocytometer. To assess proliferation, 1 X 106 leukemic 
cells were stained in 1 mL media containing 1 ml CellTrace CFSE dye (stock 5 
mM) for 20 minutes at room temperature. To remove unincorporated CFSE, cells 
are diluted with 5 mls media and then resuspended in 10 mls media. A 1 mL aliquot 
was analyzed by flow cytometry each day. CFSE MFI is normalized to day 0.  
 
To determine whether dexamethasone and ESRRB agonists synergize to induce 
leukemic cell death, the IC50 was estimated using the drc package (drc_3.0-1) in 
R 3.6.0 with lower bound set to 0. The Combination Index (CI) was calculated using 
the formula a/A + b/B and the Chou-Talalay Method266 where CI< 1 reflects 




Total RNA was extracted using Trizol and cDNA synthesized from RNA (2 μg) 
using Superscript First-Strand Synthesis System (Invitrogen). qRT-PCR was 
performed on the AB7300 Detection System (Applied Biosystems) using POWER 
SYBR Green Master Mix (Applied Biosystems) and gene-specific primers. Gene 
expression was determined using the ΔΔ cycle threshold method and normalized 




RNA-sequencing and ChIP-qPCR  
RNA was isolated from mouse T-ALL cells infected with non-silencing, Nr3c1 or 
Esrrb shRNAs treated with vehicle or dexamethasone for 6 hours using the 
Invitrogen RNA mini kit. RNA was sent to BGI (HTTPS://WWW.BGI.COM/US/) 
where library preparation, fragmentation and paired-end multiplex sequencing 
were performed. RNA-sequencing results were quantified using RSEM49. 
Heatmap represents differentially expressed genes between vehicle (DMSO) and 
dexamethasone treated non-silencing cells using a Log2 fold cut-off (n= 3 
replicates). For chromatin immunoprecipitation, approximately 1 x 107 human ALL 
cells (KOPTK1) were treated with dexamethasone or vehicle (DMSO) for 12 hours. 
Cells were harvested and resuspended in serum-free media, crosslinked in 1% 
formaldehyde for 10 min. Fixation was terminated by adding glycine to a final 
concentration of 0.125M and cells were resuspended in lysis buffer (10 mM Tris-
HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 0.5 mM EGTA; 0.1% sodium 
deoxycholate; 0.5% N- lauroylsarcosine), washed and sonicated for 30 minutes 
using Bioruptor. The supernatant was then subjected to immunoprecipitation with 
an ESRRB antibody (3 μg) overnight or mouse IgG (Santa Cruz). Magnetic IgG 
beads were added to the chromatin and isolated with a magnet. Beads were 
reverse cross-linked and DNA was precipitated and quantified using quantitative 
PCR with SYBR green reagent. Quantification was completed using the ΔΔ cycle 
threshold (CT) using primers to the ERRE in the GR target genes examined. 
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Percent input was normalized to IgG control. Specific primer sequences are 
provided in table A.2  
 
Hi ChIP  
1x107 Mouse T-ALL cells were washed in serum free medium and crosslinked for 
10 minutes in 1% formaldehyde solution. Glycine (125 mM) was used to quench 
the crosslinking reaction. Cells were then pelleted and lysed using Hi-C lysis buffer 
and incubated at 4°C for 30 minutes. Nuclei were pelleted by centrifugation at 2500 
RCF for 5 min at 4°C and washed once with ice-cold Hi-C Lysis buffer. After 
removing supernatant, nuclei were resuspended in 100 μl of 0.5% SDS and 
incubated at 62°C for 10 minutes. The reaction was quenched by adding 335 μL 
of 1.5% Triton X-100 and incubating for 15 minutes at 37°C. After the addition of 
50 μl of 10X NEB Buffer 2 and 375 U of MboI restriction enzyme, chromatin was 
digested at 37°C for 2 hours with rotation and MboI enzyme was heat inactivated 
by incubating the nuclei at 62°C for 20 min. 52 μl of fill-in master mix (37.5 μl of 0.4 
mM biotin-dATP, 1.5 μl of 10 mM dCTP, 1.5 μl of 10 mM dGTP, 1.5 μl of 10 mM 
dTTP, and 10 μl of 5 U/mL DNA Polymerase I, Large (Klenow) Fragment) was 
added and the tubes were incubated at 37°C for 1 hour with rotation. Proximity 
ligation was done by adding 947 μl of ligation master mix (150 ul of 10X T4 DNA 
ligase buffer, 125 μl of 10% Triton X-100, 7.5 μl of 20 mg/ml BSA, 10 μl of 400 
U/mL T4 DNA ligase, 655.5 μl of water), followed by incubation at room 
temperature for 4 hours with rotation. After proximity ligation, nuclei were pelleted 
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by centrifugation at 2500 rcf. for 5 minutes and resuspended in 1ml of nuclear lysis 
buffer. Nuclei were sonicated using a Covaris ME220 for 6 minutes. Sonicated 
chromatin was clarified by centrifugation at 16,100 rcf. for 15 min at 4°C. Pre-
clearing of sonicated lysate was done by addition of 60 μl of protein G magnetic 
beads to the sonicated chromatin and incubated for 1 hour at 4°C with rotation. 
Beads were then separated on a magnetic stand and the supernatant was 
transferred to a new tube. 7.5 μg of H3K27ac antibody (ABCAM, ab4729) was 
added to the tube and incubated overnight at 4°C with rotation. The next day, 60 
μl of protein G magnetic beads were added to each sample tube and the tubes 
were incubated for 2 hours at 4°C with rotation. Beads were then separated on a 
magnetic stand and washed three times with 1 ml of high salt sonication buffer 
followed by three washes with 1 ml of LiCl wash buffer and one wash with 1 ml of 
TE with salt. Beads were then resuspended in 200 ml of elution buffer and 
incubated at 65°C for 15 minutes to elute. Protein was degraded by the addition of 
10 μl of 20 mg/mL proteinase K and incubated at 55°C for 45 minutes. Samples 
were then incubated at 65°C for 5 hours to reverse crosslinks. DNA was then 
purified using Zymo DNA Clean and Concentrate 5 columns (Zymo, D4013) 
according to manufacturer’s protocol and eluted in 14 μl of water. The amount of 
eluted DNA was quantified using Qubit dsDNA HS kit (Invitrogen, Q32854). 
Tagmentation of ChIP DNA was performed using the Illumina Nextera DNA Library 
Prep Kit (Illumina, FC- 121-1030). In short, 5μl of streptavidin C1 magnetic beads 
(Invitrogen, 65001) was washed with 1 ml of tween wash buffer and resuspended 
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in 10 mL of 2X biotin binding buffer. 50ng purified DNA was added in a total volume 
of 10 μl of water to the beads and incubated at room temperature for 15 minutes 
with gentle agitation. The beads were then separated with a magnet and the 
supernatant was discarded. Beads were washed twice with 500 μl of tween wash 
buffer and incubated at 55°C for 2 minutes with shaking each time. Tagmentation 
was performed by resuspending the beads in 25 μl of Nextera Tagment DNA 
buffer, 2.5μl of Nextera Tagment DNA Enzyme 1 and 22.5 μl of Nextera 
Resuspension Buffer and incubation was carried out at 55°C for 10 minutes with 
shaking. The beads were then separated on a magnet and supernatant was 
discarded. The beads were washed with 500 μl of 50 mM EDTA at 50°C for 30 
minutes, washed again three times with 500 μl of tween wash buffer at 55°C for 2 
minutes each, and once with 500 μl of 10 mM Tris-HCl pH 7.5 for 1 minute at room 
temperature. To generate the sequencing library, PCR amplification of the 
tagmented DNA was performed while the DNA is still bound to the beads. DNA 
was amplified with 12 cycles of PCR. After PCR, beads were separated on a 
magnet and the supernatant containing the PCR amplified library was transferred 
to a new tube and the libraries were size selected to 300-700 bp directly using the 
Ampure beads according to manufacturer’s protocol. DNA was purified and 
sequenced using 50bps paired-end library by BGISeq500. Sequencing read pairs 
were aligned and assessed using HiC-Pro version 2.11.1.51 By using the MboI 
^GATC cutsite, mm10 genome were cut into fragments using the digest_genome 
package provided by HiC-Pro. After the alignment using HiC-Pro, the Hi-ChIP 
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interaction were called using hichipper version 0.7.7. Hichipper utilizes MACS2 on 
peak calling with –extsize 147 – nomodel and q-value < 1e-5 and calling the peaks 
on the valid read pairs from HiC-Pro output. Using these peaks as anchor point, 
hichipper calls both intra-chromosomal interactions and inter-chromosomal 
interactions. The interactions bedpe were then transform to bigBed file and 
visualize on UCSC genome browser. Virtual 4C interactions were visualized by 
converting interactions that have one side overlapping a given viewpoint into 
alignment format (.bam) and using this to plot the read count of interaction signal 
























Figure 2.1. The orphan nuclear receptor ESRRB regulates 
glucocorticoid-induced cell death in vitro and in vivo. ESRRB was 
identified as a mediator of GC resistance in a whole genome mouse shRNA 
screen using the whole genome TRC shRNA library (A). ESRRB contains a 
ligand binding and DNA binding domain that binds an ERRE site and 
mediates transcriptional changes via the recruitment of co-activator or co- 
repressor proteins to its AF2 domain (B). Mouse T-ALL cells (1390) were 
transduced with lentiviruses expressing a Non-silencing (NS) control or two 
independent shRNAs targeting mouse Esrrb (1, 2) or Nr3c1 and Esrrb and 
Nr3c1 mRNA expression was analyzed by quantitative real-time PCR. Copy 
number was normalized to β-actin using the ΔΔCT (C). Knockdown of Esrrb 
in mouse T-ALL cells 1 (1390) and 2 (5059) results in resistance to 
dexamethasone-induced apoptosis. Mouse T-ALL cells expressing NS or 
Esrrb-shRNAs were cultured with dexamethasone (50nM) for 2 days and 
apoptosis was assayed by Annexin V-FITC/7-AAD staining followed by flow 
cytometry (D/F). ESRRB repression significantly shifts the dexamethasone 
GI50. Non-silencing cells or cells deficient for ESRRB or NR3C1 were 
cultured in increasing concentrations of dexamethasone for 48 hours and 
viability was assayed by MTS. Absorbance values were normalized to 
vehicle control (E/G). Experimental approach to examine dexamethasone 
response in vivo (H). Esrrb or Nr3c1 knockdown mediates dexamethasone 
resistance in vivo. Kaplan- Meier survival curve demonstrates that 
dexamethasone significantly delays disease in mice transplanted with mouse 
T-ALL cells transduced with NS shRNA (I) but has no effect on mice 
transplanted with Nr3c1- (J) or Esrrb- (K) gene specific shRNAs (n=5-7 mice 
per group; statistics by log rank test). The results are averages of three 
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Figure 2.2. An ESRRB-deficiency reduces nuclear ESRRB levels but 
does not affect the leukemic gene expression signature or alter 
leukemic growth in vitro or in vivo. Immunoblot analysis shows that 
ESRRB localizes to the nucleus in mouse T-ALL cells and Esrrb shRNAs 
reduce nuclear ESRRB levels (A). Carboxyfluorescein succinimidyl ester 
(CFSE) staining and leukemic cell viability of non- silencing and Esrrb-
deficient mouse T-ALL cells (B/C). Differential gene expression plot of RNA-
sequencing analysis shows minimal variation in gene expression profile 
between NS and Esrrb knockdown cells by log10 differential expression (D). 
Kaplan-meier survival curve of mice transplanted with NS or Esrrb knockdown 
leukemia cells reveals no significant effects on disease latency (n=5-7 mice 
per group) (E). The results are averages of three independent experiments 
















Figure 2.3 ESRRB cooperates with GR to potentiate dexamethasone-
induced gene expression. RNA was isolated from mouse T-ALL cells infected 
with non-silencing (NS), Nr3c1 or Esrrb shRNAs treated with vehicle (DMSO) or 
dexamethasone (100 nM) for 6 hours and sequenced using BGI-seq 500. RNA-
sequencing results were quantified using RSEM. Heatmap represents 
differentially expressed genes between vehicle and dexamethasone treated NS 
cells using Log 1.5-fold cut-off (n= 3 replicates) (A). GSEA on dexamethasone-
induced gene set shows significant negative correlation in Esrrb knockdown 
leukemic cells treated with dexamethasone (p<.001) (B Top). Bar graph showing 
the distribution of log fold change across detected genes. The NS cells exhibit 
the highest average log fold change when treated with dexamethasone, while 
Nr3c1- or Esrrb-knockdown interferes with optimal changes in gene expression 
(B bottom). Nr3c1, Bcl2l11, and Tsc22d3 are GR-regulated genes dependent on 
ESRRB for their expression. Control or Esrrb knockdown cells (2 independent 
shRNAs) were treated with dexamethasone for 6 hours and Nr3c1, Bcl2l11 and 
Tsc22d3 mRNA expression was analyzed by quantitative real-time PCR. Copy 
number was normalized to β-actin using the ΔΔCT (C). BIM protein expression 
was analyzed by immunoblot after 12 hours dexamethasone (100nM) treatment 
in non-silencing, Nr3c1 or Esrrb knockdown cells. Protein was quantified using 
densitometry and normalized to ACTIN (D). The results are averages of three 
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Figure 2.4 Dexamethasone regulates diverse cellular pathways. Scatter 
plots showing differentially expressed genes in NS cells (A) and Nr3c1 
knockdown cells (B) treated with DMSO or dexamethasone (100 nM). Yellow 
dots represent significantly upregulated genes and blue dots represent 
significantly downregulated genes using log2 cutoff. Dexamethasone functions 
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Figure 2.5. A subset of genes repressed by dexamethasone treatment 
are dependent on ESRRB. RNA was isolated from mouse T-ALL cells 
infected with non- silencing, Nr3c1 or Esrrb shRNAs treated with DMSO or 
dexamethasone for 6 hours and sequenced on the BGI-seq 500 platform. 
RNA-sequencing results were quantified using RSEM. Heatmap represents 
differentially expressed genes between DMSO and dexamethasone treated 
non-silencing (NS) cells using a log 1.5-fold cut-off (n= 3 replicates) (A). 
Quantification of GC repressed genes dependent on ESRRB or NR3C1 for 
their expression using log 2-fold cut-off (B). Validation of glucocorticoid 
repressed, Esrrb-dependent genes. NS or Nr3c1- or Esrrb-knockdown 
leukemic cells were treated with DMSO or dexamethasone for 6 hours and 
Bcl2l1, Rag1 and Klf3 mRNA analyzed by quantitative real-time PCR. Copy 
number was normalized to β-actin using the ΔΔCT (C). BCL2 inhibition re-
sensitizes Esrrb knockdown cells to dexamethasone-induced cell death. 
Mouse T-ALL cells (1390) were treated with DMSO, dexamethasone (10 nM), 
ABT-263 (5 mM), or the combination for 48 hours and apoptosis was 
quantified by Annexin V-FITC/7-AAD staining followed by flow cytometry (D). 
The results are averages of three independent experiments and error bars 













Figure 2.6: GBS- and ERRE-containing cis-regulatory elements interact 
with promoter regions of ESRRB and GR regulated genes in mouse T-ALL 
cells. Pie chart showing distribution of ERREs in GR-regulated, ESRRB-
dependent genes (A). H3K27Ac Hi- ChIP tracks of 3 ESRRB/GR-dependent 
mouse genes show pre-existing promoter interactions with active ERRE-
containing enhancers known to bind the GR. Straight black lines mark DNA 











































Figure 2.7. GBS- and ERRE-containing cis-regulatory elements interact with 
promoter regions of GR- and ESRRB-dependent genes in mouse T- ALL 
cells. Hi-ChIP tracks for 3 ESRRB and GR regulated genes in 2 additional 
mouse T-ALL cell lines (720 and 1390) reveal pre-existing interactions between 























































































































































































































































































Figure 2.8. ESRRB knockdown in human T-ALL cells confers 
dexamethasone resistance, but ESRRB does not form a complex with the 
GR. A GR/ESRRB complex in not detected in dexamethasone treated ALL cells 
or transfected HEK293T cells. KOPTK1 cells were treated with DMSO or 
dexamethasone (1 µM) for 1 hr and nuclear lysates were immunoprecipitated 
with a NR3C1 antibody followed by immunoblotting with an ESRRB antibody (A). 
HEK293T cells were transfected with an ESRRB-FLAG plasmid for 24 hours, 
treated with dexamethasone (1 µM) for 1 hour and lysates immunoprecipitated 
with an anti-FLAG antibody followed by immunoblotting with an ESRRB or 
NR3C1 antibody (B). The human T-ALL cell line KOPTK1 was transduced with 
lentiviruses expressing a Non-silencing control (NS) or with 2 shRNAs targeting 
ESRRB (shESRRB_1 and_3) or one shRNA targeting NR3C1 (shNR3C1_1) and 
ESRRB or NR3C1 mRNA expression was analyzed by quantitative real time 
PCR. Copy number was normalized to β-actin using the ΔΔCT (C). Knockdown 
for ESRRB and NR3C1 was determined as in C for NALM6 (D). ESRRB protein 
levels were assayed by immunoblotting in DND-41 cells transduced with NS or 3 
independent ESRRB shRNAs- 1,-2,-3 and protein levels determined by 
densitometry (E). Leukemic cells were treated with DMSO or dexamethasone for 
72 hours and apoptotic cells quantified by Annexin V- FITC/7-AAD staining 
followed by flow cytometry (F). Optimal dexamethasone-induction of NR3C1, 
BCL2L11 and TSC22D3 expression requires NR3C1 and ESRRB. Control or 
knockdown cells were treated with dexamethasone for 24 hours and NR3C1, 
BCL2L11 and TSC22D3 mRNA expression was analyzed by quantitative real-
time PCR. Copy number was normalized to β-actin using the ΔΔCT (G). The 
results are averages of three independent experiments and error bars represent 











Figure 2.9: Dexamethasone increases H3K27Ac levels and promoter/
enhancer interactions in canonical GC-regulated genes in human T-ALL 
cells. H3K27Ac Hi-ChIP tracks (top) showing interaction between H3K27Ac 
regions in canonical GC target genes PIK3IP1 (A), FKBP5 (B), TSC22D3 (C) and 
BCL2L11 (D) treated with DMSO (pink track) or dexamethasone (blue track). 
Black lines indicate the anchors of interaction. Virtual 4C extract from HiChIP 
(bottom) shows interaction frequency from the viewpoint (red highlight) for GC 
target genes PIK3IP1 (A), FKBP5 (B), TSC22D3 (C) and BCL2L11 (D) treated 
with DMSO (yellow) or dexamethasone (blue). ESRRB binding sites were 
determined using ERRE consensus site AAGGTCA. GR binding sites were 
determined using published ChIP sequencing data in T-ALL patient samples. 
Using Hi-ChIP data for BCL2L11, we model ESRRB regulation of GC-induced 
gene expression. Dexamethasone triggers GR and ESRRB and coactivator 
binding to the BCL2L11 enhancer (red) which loops back to the promoter (green) 
to recruit RNA polymerase II and the transcription initiation complex, thereby 











Figure 2.10. ESRRB regulates dexamethasone-induced gene 
expression and cell death in human ALL cell lines. The human T-ALL 
cell line DND-41 and the human pre-B-ALL cell line NALM-6 were 
transduced with lentiviruses expressing a Non-silencing (NS) control or 
shRNAs targeting ESRRB or NR3C1 were cultured in increasing 
concentrations of dexamethasone for 72 hours and viability was assayed by 
MTS. Absorbance values were normalized to vehicle control (A and D). 
ESRRB knockdown in human T-ALL cells confers resistance to 
dexamethasone-induced apoptosis. Silenced cells were cultured with 
dexamethasone for 2 days and apoptosis was assayed by Annexin V-FITC/
7-AAD staining followed by flow cytometry (B and E). Optimal 
dexamethasone-induced NR3C1, BCL2L11 and TSC22D3 gene expression 
requires NR3C1 and ESRRB. Control or knockdown cells were treated with 
dexamethasone for 24 hours and NR3C1, BCL2L11 and TSC22D3 mRNA 
expression was analyzed by quantitative real- time PCR. Copy number was 
normalized to β-actin using the ΔΔCT (C and F). The results are averages 
of three independent experiments and error bars represent s.e.m. *p<0.05, 




Figure 2.11. Dexamethasone increases ESRRB expression and binding 
to GR regulated genes. Human T-ALL cell lines DND-41 and KOPTK1 were 
treated with dexamethasone for 6 hours and ESRRB expression was 
quantified in nuclear lysates by immunoblotting with an ESRRB antibody. 
ESRRB protein levels is quantified by densitometry (A). ESRRB binds GC 
target genes in dexamethasone-sensitive (KOPTK1) but not resistant 
(CUTLL1) human T-ALL cells. Schematic showing putative ERRE sites in 
introns of GR target genes (B top, C top, D top). ChIP was performed with an 
ESRRB antibody or an IgG control and DNA was quantified using quantitative 
PCR using ΔΔCT with primers to the putative ESRRB binding sites. Percent 
input was normalized to IgG control (B,C,D bottom). The results are averages 






























































































Figure 2.12. Dexamethasone increases ESRRB protein levels in GC 
sensitive but not resistant human T-ALL cell lines. Human T-ALL cell lines 
KOPTK1 and CUTLL1 were treated with dexamethasone for 6 hours and 
nuclear ESRRB protein levels were measured by immunoblotting with an 
ESRRB antibody. ESRRB protein levels were quantified by densitometry (A). 
Schematic showing regions used as negative controls for ESRRB ChIP: the 
promoter regions of BCL2L11 (B) and TSC22D3 (C) (top). ChIP-qPCR was 
performed in KOPTK1 cells with an ESRRB antibody or an IgG control. 
Following ChIP, DNA was quantified by PCR using primers to the negative 
site using the ΔΔCT method. Percent input was normalized to IgG control 
(B,C bottom). The results are averages of three independent experiments and 
































































































































































































































































Figure 2.13 . ESRRB expression is reduced in a subset of relapsed ALL 
samples and dexamethasone increases ESRRB expression in human T-ALL 
cells and relapsed T-ALL samples. Analysis of published microarray data 
(GSE28460) on paired ALL patient samples reveals that ESRRB is significantly 
decreased at relapse in a subset of ALL patient samples (n= 49) (A). ESRRB 
promoter methylation was analyzed in paired ALL samples (n= 12) using published 
microarray data (GSE28461) (B). Microarray data (GSE66708) of published GC 
sensitive and resistant patients (n= 52 GC sensitive; 32 GC resistant) was 
analyzed for ESRRB expression levels (C). Microarray data (GSE57795) from 
sensitive or resistant B-ALL patient samples engrafted in NSG mice (D). 
Microarray data (GSE13204) showing ESRRB mRNA levels in genetic subtypes 
of B-ALL compared to T-ALL and healthy bone marrow (E). RNA sequencing data 
showing ESRRB mRNA levels between genetic subtypes of T-ALL (TAL1 N=85, 
TAL2 N=10, TLX1 N=24, TLX3 N=45, HOXA N=34, LMO1/2 N=10, LMO2_LYL1 
N=18, NKX2_1 N=14)(F). ESRRB is expressed in GC resistant T-ALL patient 
samples. Dexamethasone resistant T-ALL patient samples (N=4) were expanded 
in NSG mice and ESRRB protein levels were assayed by immunoblotting (G). 
Dexamethasone treatment increases ESRRB mRNA levels in human KOPTK1 
cells and relapsed T-ALL patient samples. KOPTK1 cells were treated with 
dexamethasone for 6 hrs and primary patient samples were treated with 
dexamethasone for 12 hours and ESRRB mRNA expression was analyzed by 
quantitative real-time PCR. Copy number was normalized to β-actin using the 
ΔΔCT(H). Published ChIP-seq data from GSE58266 shows increased GR binding 
to the distal promoter region of the human ESRRB gene in an ALL patient treated 
with dexamethasone(I). Significance was calculated by unpaired T-test. The 
results are averages of three independent experiments and error bars represent 











Figure 2.14. The ESRRB agonist GSK4716 synergizes with dexamethasone 
to induce human leukemic cell death. 
Dexamethasone and DY131 dual treatment increase GC-induced apoptosis in 
human ALL cells in vitro. Human ALL cell lines were treated with vehicle (DMSO), 
dexamethasone (1 µM), DY131 (10 µM) or Dexamethasone + DY131 in 
combination for 72 hours and apoptosis was assayed by Annexin V-FITC/7- AAD 
staining followed by flow cytometry (A). Dexamethasone and DY131 dual 
treatment increase dexamethasone-induced gene expression in the human T-
ALL cell line KOPTK1 in vitro. Cells were treated with vehicle, dexamethasone (1 
µM), DY131 (10 µM), or dexamethasone + DY131 in combination for 24 hours 
and NR3C1, BCL2L11 and TSC23D3 expression analyzed by quantitative real-
time PCR. Copy number was normalized to β-actin using the ΔΔCT. (B). T-ALL 
patient samples are sensitive to dexamethasone and DY131 dual treatment. 
Cells were treated with vehicle, dexamethasone (50 nM) and/or DY131 (50 µM) 
and cell viability was assayed by CellTiterGlo (C). Treatment with 
dexamethasone and GSK4716 increases GC-induced apoptosis in human ALL 
cells in vitro. Human ALL cell lines were treated with vehicle (DMSO), 
dexamethasone (1 µM), GSK4716 (10 µM) or Dexamethasone + GSK4716 in 
combination for 72 hours and apoptosis was assayed by Annexin V-FITC/7-AAD 
staining followed by flow cytometry (D). ESRRB agonists GSK4716 and DY131 
require ESRRB to induce leukemic cell death. Non-silencing or ESRRB deficient 
mouse T-ALL cells were treated with DY131 or GSK4716 (10 µM) for 48 hours 
and apoptosis was assayed by Annexin V-FITC/7-AAD staining followed by flow 
cytometry (E) GSK4716 synergizes with dexamethasone to induce human 
leukemic cell death. Human T-ALL cell lines (KOPTK1 and DND-41) were treated 
with increasing doses of GSK4716 and dexamethasone and cell viability was 
determined by CellTiterGlo. The combination index (CI) was calculated using the 
formula a/A + b/B. Synergisms, additive effect and antagonism of combined 
treatment assays are defined as CI< 1, CI = 1 and CI > 1, respectively (F). The 
results are averages of three independent experiments and error bars represent 




Table 2.1. ESRRB regulates pro-apoptotic gene expression in ALL 
The top 20 hits from gene ontology analysis on ESRRB dependent genes 
defined in figure 2.3

Term Count % PValue
GO:0009968~negative 








organism process 108 77.69784173 1.61E-04
GO:0010648~negative 




regulation of signaling 20 14.38848921 1.86E-04
GO:0012501~programmed 
cell death 26 18.70503597 3.75E-04
GO:0006915~apoptotic 
process 25 17.98561151 4.41E-04






signaling 33 23.74100719 8.58E-04
GO:0009966~regulation of 


















response to stimulus 36 25.89928058 0.001937233
GO:0010942~positive 
regulation of cell death 12 8.633093525 0.002445849
GO:1902532~negative 












Table 2.2. ESRRB regulates anti-inflammatory gene expression in ALL  
The top 20 hits from gene ontology analysis on ESRRB dependent genes 
defined in figure 2.5

Term Count % PValue
GO:0002474~antigen 
processing and presentation 




processing and presentation 7 0.080137378 6.29E-06
GO:0048002~antigen 








process 20 0.228963938 4.52E-05
GO:0030154~cell 
differentiation 27 0.309101317 8.92E-05
GO:0002479~antigen 
processing and presentation 
of exogenous peptide 




processing and presentation 
of exogenous peptide 
antigen via MHC class I
4 0.045792788 1.72E-04
GO:0048869~cellular 






development 18 0.206067544 3.65E-04
GO:0007275~multicellular 
organism development 29 0.33199771 6.22E-04
GO:0002478~antigen 
processing and presentation 








cell differentiation 15 0.171722954 9.41E-04
GO:0002521~leukocyte 






structure development 30 0.343445907 0.0017029
GO:0033077~T cell 
















shRNA Rank count.poolA count.poolB Average reads
Co-activator proteins
TRCN0000071203:Ep300 21 5243 20286 12764.5
TRCN0000095080:Ncoa4; 408 534 757 645.5
TRCN0000126149:Ncoa5 1073 167 330 248.5






SOX2 repression results in 
glucocorticoid resistance in ALL through 
activation of MAPK signaling 
 
Data from the following chapter are part of an unpublished manuscript in 
preparation: 
 
Gallagher KM, et al. SOX2 repression results in glucocorticoid resistance in 
ALL through activation of MAPK signaling 
 
All figures were generated by Kayleigh Gallagher with contributions from Justine 






T-ALL is an aggressive hematologic malignancy in children and young 
adults that frequently becomes treatment-refractory and relapses. Although cure 
rates have improved with intensified multi-agent chemotherapy, relapsed or 
treatment refractory disease remains difficult to treat with probability of survival 
after relapse of only 30%267. Glucocorticoids are critical components of multi-agent 
chemotherapy for lymphoid malignancies59. Of the lymphoid malignancies, ALL is 
the most common malignancy of childhood and involves transformation of B- or T- 
lymphoid progenitors14. In ALL patient outcome can be predicted with in vitro and 
in vivo response to glucocorticoid therapy83,84. Therefore, understanding 
mechanisms by which cells become resistant to glucocorticoids is key to 
developing better therapeutic strategies. In lymphoid cells, synthetic GCs such as 
dexamethasone induce cell cycle arrest and apoptosis by stimulating GR 
translocation to the nucleus where it binds DNA to induce or repress gene 
transcription85. In lymphoid cells the BCL2L11 locus is in an open conformation 
and GCs stimulate BCL2L11 transcription, increase proapoptotic BIM protein 
levels, to trigger apoptosis of normal and malignant lymphocytes258.  As BIM 
induction is critical in glucocorticoid induced apoptosis, an impaired GC response 
in ALL can reflect epigenetic deregulation with increased DNA methylation of 
BCL2L11 locus observed in a subset of GC resistant patients 138.  
BIM-independent mechanisms of resistance also exist where cells 
upregulate pro-survival signaling pathways to combat the pro-apoptotic 
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glucocorticoid response. Pathways implicated in glucocorticoid resistance include 
MAPK, WNT, IL-7, JAK/STAT, and FLT3131–133,136,137. Inhibition of these pathways 
can re-sensitize cells to dexamethasone in vitro, but GC sensitizers have yet to 
enter the clinic.  
To elucidate GC resistance mechanisms in ALL, we performed an shRNA 
screen in primary mouse T-ALL cells isolated from a Tal1/Lmo2 mouse T-ALL 
model.  Interestingly we identified several members of the SOX transcription factor 
family and examined the role of SOX2 repression in GC resistance. We found that 
a SOX2 deficiency confers dexamethasone resistance in mouse and human ALL 
cells.  Consistently, we show that a subset of relapse ALL patients exhibit promoter 
methylation and decreases in SOX2 expression levels. Our data suggest SOX2 
repression stimulates pro-survival gene expression including activation of EGFR 
and MAPK pathways. We find that EGFR is upregulated in resistant ALL patient 
samples which raise the possibility that EGFR inhibitors may re-sensitize relapsed 











Knockdown of Sox2 mediates GC resistance in vitro and in vivo  
 
As relapse and GC resistance remain critical issues in the treatment of ALL 
patients, our lab performed a whole genome shRNA screen to identify novel GC 
resistance genes (See Figure 2.1A). This screen identified 7 members of the SOX 
gene family of transcription factors (Table 3.1). SOX transcription factors regulate 
cell fate and development in multiple tissues and are implicated in cancer268. In 
chapter II we discussed the role of ESRRB in GC resistance in ALL. Interestingly, 
ESRRB and SOX2 cooperate in the regulation of ES cell gene expression181, 
suggesting that like ESRRB (Chapter II)269 SOX2 may also contribute to GC 
resistance. To investigate the effect(s) of a SOX2 deficiency on the 
dexamethasone response in T-ALL, we generated Sox2-deficient mouse T-ALL 
cell lines by lentiviral infection and confirmed knockdown by RT-qPCR (Figure 3.1 
A). We then examined the effect of Sox2 knockdown on sensitivity to 
dexamethasone in comparison to mouse T-ALL cells where the glucocorticoid 
receptor (GR: Nr3c1) was knocked down as a positive control.  We treated 2 
independent mouse T-ALL cell lines (1390 and 5059) with increasing 
concentrations of dexamethasone and examined effects on leukemic cell viability. 
Mouse T-ALL cells expressing a Sox2 shRNA had an altered dexamethasone GI50 
(Figure 3.1 B). Sox2 knockdown shifted the dexamethasone GI50 9.3 fold in mouse 
T-ALL cell line 1 (1390) and 5.2 fold in mouse T-ALL cell line 2 (5059) (Figure 
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3.1B). Furthermore, AnnexinV/7AAD staining followed by flow cytometry, revealed 
that Sox2 repression interferes with dexamethasone-induced apoptosis in both 
mouse T-ALL cell lines examined (Figure 3.1 C,D). The dexamethasone response 
may be different in vivo due to the presence of survival factors such as IL-7 and/or  
WNT ligands131,136. Therefore, we tested whether Sox2 knockdown mediates GC 
resistance in vivo in a leukemic mouse model. To test this, we transplanted 
syngeneic mice with a mouse T-ALL cell line (1390) expressing a non-silencing 
(NS) or Sox2-specific shRNA and treated the mice with vehicle or dexamethasone 
(15mg/kg) for 3 weeks. Mice were then monitored for leukemic growth for up to 60 
days (Figure 3.1 E). Dexamethasone treatment of mice transplanted with leukemic 
cells expressing a NS shRNA significantly extended survival and reduced 
penetrance, eliminating disease in 3 of 7 mice (Figure 3.1 F). However, mice 
transplanted with Sox2-deficient leukemia cells failed to respond to 
dexamethasone in vivo, with 3/3 mice succumbing to leukemia at the same time 
as vehicle treated mice (Figure 3.1 F). Together these data reveal that a Sox2 
deficiency in mouse T-ALL cells confers resistance to dexamethasone in vitro and 
in vivo. This finding is in contrast to the role of SOX2 in other cancer types, where 







SOX2 partners, OCT-4 and NANOG, do not influence GC response 
 
In embryonic stem (ES) cells, SOX2, OCT-4 and NANOG, cooperate to 
maintain pluripotency by activating gene expression199,200,232. As OCT-4 and 
NANOG share functions with SOX2 in ES cells, we tested whether these proteins 
had similar effects on the GC response in T-ALL cells. We generated OCT-4 and 
NANOG-deficient mouse T-ALL cells (Figure 3.2) and treated these leukemic cells 
with increasing concentrations of dexamethasone and measured cell viability by 
MTS assay. We found that Pou5f1 (OCT-4) or Nanog knockdown did not alter the 
dexamethasone GI50 (Figure 3.2 A). Similarly, we treated cells deficient for these 
factors with dexamethasone for 48 hours and assayed apoptosis by 
AnnexinV/7AAD staining followed by flow cytometry. Neither OCT-4 nor NANOG 
repression prevented dexamethasone-induced apoptosis (Figure 3.2 B). 
Importantly we validated that we achieved significant knockdown of Pou5f1 and 
Nanog by real time-qPCR (Figure 3.2 C).  These data reveal that SOX2 effects on 
the dexamethasone response occur independently of OCT-4 and NANOG and 








SOX2 deficiency alters GC response in human ALL 
 
As our shRNA screen was performed in mouse T-ALL cells, we tested 
whether SOX2 influences the GC response in human ALL cells. We measured 
SOX2 expression levels in paired T-ALL samples obtained at diagnosis and upon 
relapse and found SOX2 expression significantly decreased in relapsed ALL 
samples (Figure 3.3 A) Consistently, we detect an increase in SOX2 promoter 
methylation in these relapsed samples (Figure 3.3 B). While these data sets 
suggest a role for SOX2 in the GC response and patient outcome, it does not 
directly assess the effect of SOX2 on GC response. Using two independent 
shRNAs, we generated SOX2-deficient human T-ALL and B-ALL cell lines (Figure 
3.3) and treated them with increasing concentrations of dexamethasone. We find 
that a SOX2-deficiency shifts the dexamethasone dose response curve in both 
DND-41 and NALM-6 (Figure 3.3 C). Furthermore, AnnexinV/7-AAD staining 
followed by flow cytometry to quantify apoptotic cells reveals significant decreases 
in dexamethasone-induced apoptosis in the SOX2-deficient human ALL cell lines 
examined (Figure 3.3 D). SOX2 levels can be indicative of a poor or promising 
prognosis depending on the cancer type270–272; our data suggest that SOX2 levels 






SOX2 repression does not interfere with GC regulation of gene expression 
 
GC resistance in ALL often results from impaired GR-mediated 
transcription102. For example, AKT activation results in phosphorylation of the 
glucocorticoid receptor (GR) at S134, which interferes with its nuclear translocation 
and GR mediated target gene expression127. To determine whether SOX2 alters 
GR transcriptional activity, we treated NS- or Sox2-deficient mouse T-ALL cells 
with dexamethasone for 6 hours and evaluated the expression of GR target genes, 
including Nr3c1, Bcl2l11, and Tsc22d3. We observe similar increases in all 
canonical GR target genes examined in dexamethasone treated NS and SOX2-
deficient leukemic cells but not in GR (Nr3c1)-deficient leukemic cells (Figure 3.4 
A-C). These data suggest that SOX2 mediates GC resistance via a mechanism 
which is independent of GR- mediated transcription.  
 
SOX2 deficient cells exhibit up-regulation of pro-survival pathways 
 
To determine how Sox2 regulates the dexamethasone response in 
leukemic cells, we performed RNA-sequencing analysis.  Sox2 knockdown in 
mouse T-ALL cells significantly increased the expression of 98 genes and down-
regulated the expression of only 3 genes (Figure 3.5 A), suggesting that SOX2 
primarily functions to repress gene expression in T-ALL cells.  KEGG pathway 
analysis revealed that Sox2  knockdown most notably resulted in MAPK activation 
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(Fig 3.5 B). Genes upregulated by Sox2 knockdown include upstream receptors: 
Egfr, Fgfr1, Pdgfra, MAPK target genes: Etv4, Etv5, Epha2, and other associated 
genes including Lrrk2, Ptk2b and Fbln1. As MAPK activation is associated with an 
increased proliferation rate273, we measured leukemic cell proliferation by labeling 
NS and SOX2-deficient leukemic cells with CFSE. A Sox2 deficiency resulted in 
significant increases in CFSE dilution over time consistent with an increase in cell 
proliferation (Figure 3.5 C). Furthermore, our findings are consistent with studies 
that correlate MAPK up-regulation with GC resistance137. We further validated 
activation of pro-survival gene expression in Sox2 knockdown by qPCR (Figure 
3.5 D). To assess the effects of Sox2 knockdown on the dexamethasone response, 
we performed RNA-sequencing on non-silencing or SOX2-deficient cells after 
treatment with DMSO or dexamethasone. We find that genes normally repressed 
by dexamethasone are upregulated in Sox2 knockdown (Figure 3.5 E). We find 
that the pathways upregulated after dexamethasone treatment in Sox2 knockdown 
are the same as the ones basally upregulated (Figure 3.5 B). This indicates that 
repression of these pathways by dexamethasone treatment may be essential for 
induction of cell death.  
Interestingly, we find upregulation of similar pro-survival genes in GC 
resistant patient samples, as was observed in Sox2 knockdown (Figure 3.6 A). We 
hypothesize that activation of these pro-survival genes inhibits the cellular 
response to dexamethasone-induction of apoptotic genes, resulting in GC 
resistance. These findings reveal that GC resistant or relapsed ALL patients that 
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suppress SOX2 may also exhibit MAPK activation, and therefore, may be good 
candidates for combination therapy that couples GC therapy with EGFR/MAPK 
inhibitor Erlotinib. We performed mutation analysis utilizing the St. Jude PECAN 
database which includes sequencing data from 1430 B-ALL patients and 397 T-
ALL patients. Mutations in EGFR were observed in only 13 patients, 3 of which 
were relapse. The majority of mutations identified were not located in the tyrosine 
kinase domain where activating mutations are found. These findings suggest that 
while EGFR is upregulated at the mRNA level, there is little evidence of activating 
mutations in ALL. Our preliminary data suggest that EGFR inhibition increases the 
dexamethasone response in resistant human T-ALL cell lines KOPTK1 and MOLT-
4 (Figure 3.6 B). This is consistent with the increase in EGFR expression observed 





 Our shRNA screen revealed several SOX TF family members as 
putative GC resistance genes. In validation studies, we pursued knockdown of the 
SOX B1 group member, SOX2, as a novel mechanism of GC resistance. Our data 
find that repression of SOX2 in mouse and human ALL alters the GC sensitivity 
(Figure 3.1 B,C; Figure 3.3 C,D) and is consistent with decreased SOX2 levels in 
a sub-set of  relapsed ALL patients, which can be at least partially attributed to an 
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increase in SOX2 promoter methylation (Figure 3.3 A,B). Our shRNA screen also 
suggests that knockdown of Sox1 mediates GC resistance (Table 3.1). Sox1 is 
also a member of the SOX B1 group and therefore may share functions with SOX2. 
SOX1 and SOX2 could be compensating for one another in these experiments and 
knocking down both these TFs may result in increased GC resistance.  
 While we validate knockdown of Sox2 as a mediator of GC 
resistance in vivo, we observe a 7-day delay in leukemia on-set in these transplant 
studies (Figure 3.1 F). This finding suggests that, while SOX2 is important for the 
GC response, it may also play a role in leukemic progression in vivo. This would 
be consistent with its importance in cancer stem cells272. SOX2 has not been 
implicated in the maintenance of leukemia-initiating cells in ALL, but this would be 
interesting to explore. Overall our data suggest that SOX2 expression would be 
favorable for the GC response in ALL and this is consistent with studies in 
squamous cell carcinoma and lung cancer where SOX2 expression correlates with 
favorable prognosis270,271.  
 GC resistance observed in Sox2 knockdown cells seems to be 
mediated by upregulation of pro-survival signaling (Figure 3.5 A-D). Interestingly, 
we find upregulation of the WNT-signaling related genes Dixdc1 and Prkaa2 
(Figure 3.5 D). DIXDC1 activates WNT/Beta-Catenin signaling by increasing 
nuclear accumulation of Beta-Catenin274, while Prkaa2 encodes the catalytic 
subunit of AMPK, which phosphorylates Beta-Catenin at Serine 552 to stabilize 
the  protein, supporting its signaling275. These data are consistent with findings in 
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other cell types where SOX2 functions to repress WNT/Beta-Catenin signaling, 
which results in activation of this pathway when SOX2 is lost246,247. This could 
explain the upregulation in Egfr and downstream MAPK signaling, as Egfr is a 
Beta-Catenin target gene276,277. Importantly other SOX family members can 
repress WNT signaling, including SOX9 and SOX17 278, which were also identified 
in our shRNA screen for GC resistance genes, indicating that SOX9 and SOX17 
may mediate GC resistance by activating the WNT pathway. In contrast, we also 
identify Sox5 in our shRNA screen, which activates WNT signaling. Therefore 
knockdown of SOX proteins may mediate GC resistance by diverse mechanisms. 
 Activation of both the WNT and MAPK  pathways have been 
previously implicated in GC resistance136,137; however, our data suggest that there 
is an important role in regulation of these pathways by SOX proteins. MAPK 
signaling downstream of receptor tyrosine kinases, including EGFR, results in 
activation of ERK1/2 which regulates expression of pro-survival genes including 
BCL-XL and MCL-1279. Activation of these proteins has been implicated in GC 
resistance251. As GC resistant patients exhibit upregulation in EGFR expression 
and downstream target genes (Figure 3.5 E), EGFR inhibitors may be a novel 
therapeutic strategy to combat GC resistant ALL. Furthermore, our data suggest 
that this strategy would be most effective in ALL patients that repress SOX 
proteins. Future studies will involve testing receptor tyrosine kinase inhibitors, 
including EGFR inhibitors, as well as inhibitors to downstream pathways to fully 
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Materials and Methods 
 
Lentiviral production and infection  
HEK-293T cells are plated at 1x106 cells per well in a 6 well tissue culture treated 
plate in DMEM containing 10% FBS. 24 hours later cells are transfected with 
PLKO.1 vector containing NS, Nr3c1 or Sox2-specific shRNAs (Supplemental 
Table 4) along with packaging plasmids containing gag and pol and envelope 
plasmids in the presence of Effectene (Qiagen). Virus is harvested and filtered 48 
hours post-transfection. Leukemic cells are plated in 12 well plates with polybrene 
(4 μg/ml) and 500 ml virus for 12 hours. Cells are then transferred to 10 cm dishes 
and subjected to puromycin selection 48 hours after infection.  
 
RNA-sequencing 
RNA was isolated from mouse T-ALL cells infected with non-silencing, Nr3c1 or 
Sox2 shRNAs using the Invitrogen RNA mini kit. RNA was sent to BGI 
(HTTPS://WWW.BGI.COM/US/) where library preparation, fragmentation and 
paired-end multiplex sequencing were performed. RNA-sequencing results were 
quantified using RSEM49 (n= 3 replicates). 
 
Mice and cells  
Tal1/Lmo2 transgenic mice were monitored for leukemia and mouse and 
human T-ALL cells were cultured as described77. All animal procedures used in 
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this study were approved by the University of Massachusetts Medical School 
Institutional Animal Care and Use Committee. 
 
Cell growth/death assays  
 To quantify apoptosis, cells were treated with increasing concentrations of 
dexamethasone (0-10μM) for 24-72 hours and 2 x 105 cells were resuspended in 
Annexin V staining buffer containing Annexin V-FITC (BD pharmigen) and 7-AAD 
(BD) for 15 minutes and Annexin V and 7-AAD-positive cells quantified by flow 
cytometry. To measure dexamethasone effects on leukemic cell viability, mouse 
or human ALL cell lines or samples were cultured in increasing concentrations of 
dexamethasone for 48 hours and metabolic activity was assayed after 5 days by 
the addition of CellTiter-Glo chemiluminescence reagent (Promega) and 
measured using a Beckman Coulter DTX 880 plate reader. Absorbance values 
were normalized to DMSO control for each patient sample and ALL cell line. 
Nonlinear dose- response curves were fitted, from which the GI50 (the 
concentration of dexamethasone at which 50% of the cells are affected) were 
calculated using GraphPad Prism 5 software (GraphPad).  
To assess proliferation, 1 X 106 leukemic cells were stained in 1 mL media 
containing 1 ml CellTrace CFSE dye (stock 5 mM) for 20 minutes at room 
temperature. To remove unincorporated CFSE, cells are diluted with 5 mls media 
and then resuspended in 10 mls media. A 1 mL aliquot was analyzed by flow 





Total RNA was extracted using Trizol and cDNA synthesized from RNA (2 μg) 
using Superscript First-Strand Synthesis System (Invitrogen). qRT-PCR was 
performed on the AB7300 Detection System (Applied Biosystems) using POWER 
SYBR Green Master Mix (Applied Biosystems) and gene-specific primers. Gene 
expression was determined using the ΔΔ cycle threshold method and normalized 





Figure 3.1 Sox2 knockdown mediates glucocorticoid resistance in vitro and in 
vivo. Mouse T-ALL cells (1390) were transduced with lentiviruses expressing a Non-
silencing (NS) control an shRNA targeting mouse Sox2 (1) and Sox2 mRNA expression 
was analyzed by quantitative real-time PCR. Copy number was normalized to β-actin 
using the ΔΔCT (A). Knockdown of Sox2 in mouse T-ALL cells 1 (1390) and 2 (5059) 
results in a shift in the dexamethasone Gi50. Non-silencing cells or cells deficient for 
SOX2 or NR3C1 were cultured in increasing concentrations of dexamethasone for 48 
hours and viability was assayed by MTS. Absorbance values were normalized to vehicle 
control (B) Mouse T-ALL cells expressing NS or Esrrb-shRNAs were cultured with 
dexamethasone (50nM) for 2 days and apoptosis was assayed by Annexin V-FITC/7-
AAD staining followed by flow cytometry (C,D). Experimental approach to examine 
dexamethasone response in vivo (E). Sox2 knockdown mediates dexamethasone 
resistance in vivo. Kaplan- Meier survival curve demonstrates that dexamethasone 
significantly delays disease in mice transplanted with mouse T-ALL cells transduced 
with NS shRNA but has no effect on mice transplanted with Sox2 gene specific shRNAs 
(n=3-5 mice per group; statistics by log rank test) (F). The results are averages of three 
independent experiments and error bars represent s.e.m. *p<0.05, **p<0.01, ***p<0.001. 
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Cont. Figure 1: Knockdown of Sox2 results in GC resistance in vitro and in vivo 





































Figure 3.2 SOX2 partners NANOG and OCT-4 do not mediate glucocorticoid 
resistance. Mouse T-ALL cells (1390) were transduced with lentiviruses 
expressing a Non-silencing (NS) control or shRNAs targeting mouse Nanog  and 
Pou5f1 (OCT-4). Knockdown of Nanog or Pou5f1 in mouse T-ALL cells id not 
result in a shift in the dexamethasone Gi50. Non-silencing cells or cells deficient 
for NANOG or OCT-4 were cultured in increasing concentrations of 
dexamethasone for 48 hours and viability was assayed by MTS. Absorbance 
values were normalized to vehicle control (A) Mouse T-ALL cells expressing NS , 
Nanog, or Pou5f1-shRNAs were cultured with dexamethasone (50nM) for 2 days 
and apoptosis was assayed by Annexin V-FITC/7-AAD staining followed by flow 
cytometry (C,D). To confirm knockdown of Nanog and Pou5f1 mRNA expression 
was analyzed by quantitative real-time PCR. Copy number was normalized to β-
actin using the ΔΔCT (C). The results are averages of three independent 
experiments and error bars represent s.e.m. *p<0.05, **p<0.01, ***p<0.001.  
















































































































































































































Figure 3.3 SOX2 repression results in glucocorticoid resistance in ALL. 
Microarray data from paired diagnostic and relapsed ALL patients were 
compared for SOX2 expression levels and SOX2 was significantly decreased in 
relapsed patients (A). Methylation data from paired diagnostic and relapse ALL 
patients reveal an increase in SOX2 promoter methylation at relapse (B). 
Knockdown of SOX2 in human ALL cell lines DND-41 and NALM-6 results in a 
shift in the dexamethasone Gi50. Non-silencing cells or cells deficient for SOX2 
were cultured in increasing concentrations of dexamethasone for 72 hours and 
viability was assayed by MTS. Absorbance values were normalized to vehicle 
control (C) Human ALL cells expressing NS or 2 independent SOX2 shRNAs 
were cultured with dexamethasone (1uM) for 3 days and apoptosis was assayed 
by Annexin V-FITC/7-AAD staining followed by flow cytometry (D). The results 
are averages of three independent experiments and error bars represent s.e.m. 




























































































Cont Figure 2: SOX2 deficiency mediates GC resistance in human 
ALL
















































































































































Figure 3.4. Sox2 knockdown does not interfere with glucocorticoid target 
gene expression. Mouse T-ALL cells (1390) were transduced with lentiviruses 
expressing a Non-silencing (NS) control or shRNAs targeting mouse Nr3c1  and 
Sox2. Cells were cultured with dexamethasone (100 nM) for 6 hours and mRNA 
expression of GR target genes Nr3c1, Bcl2l11, and Tsc22d3 was analyzed by 
quantitative real-time PCR. Copy number was normalized to β-actin using the 
ΔΔCT (C). The results are averages of three independent experiments and error 
































































































































































































































































Supp figure 3: SOX2 deficiency does not affect GC induced 
gene expression
A B C
D-F Show other GC responsive 

















































































































MAPK signaling pathway - Mus 
musculus (mouse) 4.19E-06 0.000403 KEGG
Cytokine-cytokine receptor 
interaction - Mus musculus (mouse) 0.000727 0.0378 KEGG
Mucin type O-glycan biosynthesis - 
Mus musculus (mouse) 0.000788 0.0378 KEGG
NOD-like receptor signaling pathway 
- Mus musculus (mouse) 0.00178 0.0585 KEGG
Regulation of actin cytoskeleton - 
Mus musculus (mouse) 0.00195 0.0585 KEGG
Th1 and Th2 cell differentiation - Mus 
musculus (mouse) 0.00225 0.0585 KEGG
Axon guidance - Mus musculus 
(mouse) 0.00263 0.0585 KEGG
TNF signaling pathway - Mus 
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Figure 3.5 Pathway analysis of SOX2 deficient mouse T-ALL cells reveals 
activation of MAPK and cytokine signaling.  Mouse T-ALL cells (1390) were 
transduced with lentiviruses expressing a Non-silencing (NS) control or shRNAs 
targeting mouse Sox2 and cells were subjected to RNA-sequencing. Differential 
gene expression between NS cells and Sox2 knockdown cells revealed over 100 
upregulated genes (A). KEGG pathway analysis of genes differentially expressed 
in Sox2 knockdown reveals activation of the MAPK pathway (B). NS cells or SOX2 
deficient cells were stained with CFSE and CFSE dilution was monitored at 12, 24 
and 48 hours to determine proliferation rate (C). To validate upregulation of pro-
survival genes mRNA expression of Dixdc1, Prkaa2, Egfr, Lrrk2, Ptk2b, Fbln1, 
Etv4 and Ccnd1 was analyzed by quantitative real-time PCR. Copy number was 
normalized to β-actin using the ΔΔCT (D). RNA-sequencing analysis of the 
dexamethasone induced gene expression signature reveals upregulation of genes 
normally repressed by dexamethasone in Sox2 knockdown. Non-silencing or Sox2 
knockdown cells were treated with 100 nM dexamethasone for 6 hours and gene 
expression analyzed by mRNA sequencing (E). The results are averages of three 









Figure 3.6 EGFR inhibition increases cellular response to dexamethasone. 
Microarray analysis of GC sensitive and resistant patient samples revealed up-
regulation of pro-survival genes (A). Treatment of GC resistant human ALL cell 
lines KOPTK1 and MOLT-4 with dexamethasone and erlotinib results in 
increased apoptosis. Cell lines were cultured with vehicle, dexamethasone, 
erlotinib or the combination for 72 hours and apoptosis was assayed by Annexin 
V/7AAD staining followed by flow cytometry (B). The results are averages of 





















































































































































Table 3.1. Members of the SOX family identified as putative GC resistance 
genes 
shRNA Rank count.poolA count.poolB Average reads
SOX Family Members
TRCN0000085944:Sox6 27 3904 13424 8664
TRCN0000085653:Sox17 138 856 3494 2175
TRCN0000085424:Sox1 234 463 1810 1136.5
TRCN0000085748:Sox2 391 342 1025 683.5
TRCN0000075494:Sox5 793 257 436 346.5
TRCN0000086164:Sox9 1300 68 338 203
























My thesis work has established novel mechanisms of resistance to 
glucocorticoid (GC) therapy in ALL. I have provided evidence that re-activating 
these pathways can lead to re-sensitization to glucocorticoid therapy. Both SOX2 
and ESRRB had not previously been implicated in chemotherapy response in ALL 
or in T-cell development; therefore, my work highlights a novel functions for these 
proteins in GR regulation. Increasing our understanding of GC resistance 
mechanisms allows us to identify novel therapeutic strategies to prevent 
resistance/relapse. 
 
Identification of novel mechanisms of glucocorticoid resistance by shRNA 
screening 
 Our whole genome shRNA screen identified hundreds of genes whose 
knockdown mediates resistance to dexamethasone induced apoptosis. This result 
may seem surprising as it indicates the cells can become resistant to this treatment 
by several mechanisms. Our data are consistent with other shRNA screens for 
dexamethasone resistance genes in B-ALL, where similar numbers of genes were 
identified as regulators of dexamethasone sensitivity260,280. One explanation for the 
diverse shRNA screen results may be due to progenitor-like nature of the cells 
used for screening. Less differentiated cells are more susceptible to alteration in 
cell state which would allow for greater diversity in resistance mechanisms281.  The 
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fact that cells can become resistant to dexamethasone through alteration of 
multiple pathways reflects the potential need for personalized medicine for relapse 
ALL patients. There may not be one novel therapeutic strategy for treating GC 
resistant ALL, as patients can present with different mechanisms of GC resistance. 
Our data suggest that RNA-sequencing of resistant patients may reveal repression 
of key signaling pathways for glucocorticoid-induced apoptosis and would point to 
the use of dexamethasone in combination with therapeutics which activate these 
pathways for re-sensitization.   
 
Knockdown of pluripotency factors as a mechanism of glucocorticoid 
resistance 
 
 Interestingly our work presented in this thesis implicate 2 factors important 
in ES cell regulation in GC resistance. An shRNA screen for GC resistance reveals 
that repression of either ESRRB (Chapter II) or SOX2 (Chapter III) results in 
reduced leukemic cell death upon treatment with the glucocorticoid 
dexamethasone in both mouse and human cells (Figures 2.1 D-G, 2.10, 3.1 B,C, 
3.3 C,D). Furthermore, mRNA levels of both SOX2 and ESRRB are reduced at 
relapse in ALL patients, supporting our findings (Figures 2.13 A, 3.3 A). While both 
of these proteins have been studied extensively in ES cells, neither had been 
previously implicated in T-cell biology, leukemia, or GC signaling. Our knockdown 
studies have uncovered a novel role for these proteins in the adult where ESRRB 
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acts as a cooperating GR transcription factor, essential for regulation of target 
genes by the GR (Figure 2.3, 2.7, 2.8) and SOX2 functions to inhibit pro-survival 
signaling in leukemia (Figure 3.5).  Knockdown studies of SOX2 and ESRRB in 
mouse T-ALL cells revealed minimal overlap in gene expression signatures, 
suggesting different functions of these proteins in leukemia.  
 
Knockdown of ESRRB as a mechanism of glucocorticoid resistance 
 
 In stem cells, ESRRB and SOX2 have been implicated in the same 
pathways, even functioning to regulate gene expression together181. We find that 
repression of SOX2 or ESRRB in mouse or human ALL cells in vitro and in vivo 
results in glucocorticoid resistance (Figures 2.1, 3.1). However, RNA-sequencing 
analysis of leukemia cells subjected to either ESRRB or SOX2 knockdown and 
treated with dexamethasone reveal different functions for these proteins in ALL. 
Knockdown of ESRRB resulted in minimal changes in the basal transcriptional 
signature of ALL cells. However, upon dexamethasone treatment, we observed a 
significant repression of dexamethasone mediated gene expression in ESRRB 
knockdown cells, revealing its function as a regulator of GR mediated transcription 
(Figure 2.3). We validated that ESRRB repression in fact prevents up regulation of 
known GR target genes including NR3C1, BCL2L11, and TSC22D3 (Figure 2.3 
C). Furthermore, we show that ESRRB knockdown interferes with induction of BIM 
protein levels by dexamethasone (Figure 2.3 D). ESRRB dependent genes are 
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enriched for apoptotic function (Table 2.1), which suggests that GC resistance as 
a result of an ESRRB deficiency is due to a lack of upregulation of pro-apoptotic 
genes. Furthermore, we identify a role for ESRRB in GR mediated transcriptional 
repression of pro-inflammatory signaling (Figure 2.5, Table 2.2), highlighting that 
ESRRB is important in GR repression and activation of GR target genes, which 
are both important in inducing leukemic cell death85,102. While these results 
suggested a role for ESRRB in GR-induced transcriptional changes, we definitively 
addressed this through ChIP-qPCR of GR target genes and found significant 
recruitment of ESRRB to ERRE sites within GR target genes upon dexamethasone 
treatment (Figure 2.11). Furthermore, we find ERRE sites enriched in 
dexamethasone regulated enhancer elements of GR target genes (Figure 2.9). 
These findings support a model where ESRRB binds cooperatively with GR to 
enhancer elements of GR target genes to amplify GR gene expression changes 
(Figure 2.9 E).  
Our findings are consistent with ESRRB studies in ES cells where ESRRB 
functions as a transcription factor to alter pluripotency gene expression173,176,177. 
Our studies implicating ESRRB as a key transcription factor in the GC signaling 
pathway and build on studies in developing organs where ESRRB regulates gene 
expression of various transporters and channels in the organ of Corti in the inner 
ear161. Interestingly, there may be a role for GC signaling in the Cochlea282, which 
has not been defined but suggests these proteins may cooperate during 
development.  Supporting this hypothesis, an ESRRB deficiency or a GR 
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deficiency in the heart have similar phenotypes283,284 and suggest a connection 
between ESRRB and GR signaling during cardiac development. Our model of 
ESRRB and GR cooperativity is summarized in Figure 4.1. 
 
Knockdown of SOX2 as a mechanism of glucocorticoid resistance 
 
 Our RNA-sequencing studies in SOX2 deficient revealed upregulation of 
several pro-survival pathways including MAPK, cytokine and TNF signaling (Figure 
3.5 B). Interestingly, MAPK activation has been previously implicated in 
glucocorticoid resistance and could explain the resistant phenotype observed in 
SOX2 deficient leukemic cells137. We validated upregulation of pro-survival genes 
by RT-qPCR, including genes in both the WNT and MAPK pathways (Figure 3.5 
D). Beta-Catenin mediates upregulation of Egfr and promotes downstream MAPK 
signaling277, supporting a connection between these pathways in Sox2-deficient 
leukemic cells. Furthermore, SOX2 and additional SOX family members are known 
to repress WNT signaling, so loss of these proteins often results in WNT/Beta-
Catenin activation246,247,278. We also confirmed that EGFR upregulation and 
downstream target genes could be relevant to ALL patients, as their expression is 
increased in GC resistant patients compared to GC sensitive patients (Figure 3.5 
E)  Unlike ESRRB, SOX2 had no detectable effects on GR mediated transcription 
(Figure 3.4), indicating that these proteins, while related in ES cells, have different 
functions in leukemia.  
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 Our findings regarding SOX2 in leukemia, differ from its role in other 
cancers where it works as a transcriptional activator of oncogenic signaling225–229. 
We find that SOX2 expression is essential for optimal response to the 
chemotherapeutic agent dexamethasone (Figure 3.1, 3.3) and furthermore 
knockdown of this protein increases pro-survival signaling (Figure 3.5). Overall our 
data suggest that SOX2 functions to repress gene expression in ALL and are 
consistent with data which implicate SOX2 as an activator and repressor of gene 
expression285. Our model of SOX2 regulation of pro-survival gene expression and 
GC resistance is summarized in Figure 4.2. 
 These data may be important for determining treatment strategy of ALL 
patients.  Relapse patients that exhibit SOX2 repression may be good candidates 
for MAPK or EGFR inhibitors and this could lead to increase success in the 
treatment of relapse ALL. Importantly, EGFR is also upregulated in glucocorticoid 
resistance patients (Figure 3.5 E), further supporting the use of EGFR inhibitors in 
this malignancy.  
 
Other pluripotency factors do not mediate glucocorticoid resistance 
 
 Our shRNA screen for glucocorticoid resistance mechanisms identified 2 
proteins that are key in ES cell development. Therefore, we wanted to determine 
if other ES cell factors mediate glucocorticoid resistance. Knockdown of NANOG 
and OCT-4, which are often implicated in ESRRB and SOX2 function in ES 
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cells177,179,200, did not affect glucocorticoid response (Figure 3.2 A,B). Both factors 
are in fact expressed in mouse T-ALL cell lines and significant knockdown was 
achieved (Figure 3.2 C). These data highlight that ESRRB and SOX2 functions are 
distinct in the adult vs. ES cells.  
 
GR dependent and independent mechanisms of glucocorticoid resistance 
 
 Previous work in the GC resistance field has highlighted that cells can 
become resistant to GC therapy by directly inhibiting GC signaling, but also by 
upregulating parallel pro-survival pathways to counteract the apoptotic signal 
generated by glucocorticoids125,127,130,134,136,137. Interestingly, my thesis work 
defined 2 novel mechanisms of resistance; one which works via inhibiting GR 
signaling and another which activates pro-survival pathways and works 
independently of GR signaling. Similar to studies which defined STAT3 as a key 
transcription factor in GR signaling286, my thesis work defines ESRRB as a novel 
cooperating transcription factor in the GC signaling pathway (Chapter II). In 
contrast to the STAT3 findings, where STAT3 tethers the GR to DNA to potentiate 
gene expression, we were unable to detect an interaction between ESRRB and 
the GR proteins (Figure 2.8 A.B). Furthermore, Hi-ChIP and ChIP-qPCR studies 
suggest that ESRRB regulates GR target gene transcription through binding distal 
enhancer elements (Figure 2.9). These data highlight the many models of GR 
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regulated transcription and define a novel factor important in its gene expression 
regulation. 
 Our work also builds on findings that implicated MAPK and WNT signaling 
in GC resistance136,137. Previously these pro-survival pathways had been defined 
in mediating resistance to GC-induced apoptosis. Our work implicate SOX2 protein 
in GC resistance, as our data find that SOX2 knockdown results in an upregulation 
of MAPK signaling (Figure 3.5 A-D) and we hypothesize that this could be due to 
its role in WNT inhibition. These data demonstrate a novel role for SOX2 in 
repression of pro-survival signaling in ALL.  
 
Translation to the clinic 
 
 Our findings suggest that SOX2 and ESRRB could be therapeutic targets 
in GC resistance. Therefore, a logical goal would be to activate these proteins in 
order to increase sensitivity to dexamethasone therapy. ESRRB is a nuclear 
receptor which contains druggable domains and synthetic agonists have been 
developed to activate these proteins. The compounds GSK4716 and DY131 
specifically increase ESRRB’s transcriptional activity191,192. Previously these 
compounds have been used in gastric cancer, prostate cancer and breast cancer 
to show therapeutic efficacy in vitro167,194,264. Our data show that these agents can 
be used to re-sensitize patient samples to glucocorticoid therapy in vitro (Figure 
2.14). The phenolic-acyl hydrazine structure is not favorable for in vivo studies due 
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to poor aqueous solubility. However, our work offers proof-of-concept that 
therapeutically activating ESRRB in relapse ALL could be beneficial to patients 
and highlights the need to develop new drugs/strategies to activate ESRRB.  
 My thesis work also shows that SOX2 is a critical factor for GC sensitivity in 
ALL. While some inhibitors have been developed for SOX proteins287, there 
currently is not a way to pharmacologically activate these proteins. However, our 
work shows that SOX2 knockdown results in MAPK activation and significant 
increases in EGFR levels (Figure 3.5). Therefore, patients that exhibit low SOX2 
levels may be good candidates for combined treatment with dexamethasone and 
EGFR/MAPK inhibitors. Overall my work has identified 2 targetable mechanisms 





 Our work define ESRRB as a key regulator of glucocorticoid signaling in 
ALL; however, more could be done to fully investigate the connection between 
ESRRB and the GR. ChIP-sequencing for ESRRB and GR binding sites in 
dexamethasone treated ALL cells would allow for a global understanding of how 
these proteins work together to regulate gene transcription. This experiment could 
also help to explain why some genes are dependent on ESRRB and others are 
not, as we hypothesize that ESRRB independent genes are not bound by ESRRB 
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in response to dexamethasone. Future ChIP-sequencing studies in 
dexamethasone treated ALL cell lines would address this question. It also remains 
unclear which coactivators work with ESRRB to regulate gene transcription in ALL 
cells. NCOA3 has been defined as an ESRRB co-activator in ES cells178, but mass-
spectrometry could be utilized to define the ESRRB interactome in ALL cells. This 
would allow us to better model ESRRB regulation of gene transcription in ALL. 
Finally, future directions for this project involve developing agents that can 
therapeutically activate ESRRB and can be translated in vivo. Our lab could 
collaborate with chemists to create libraries of modified ESRRB agonists which 
have improved solubility. We would then need to test these in in vitro reporter 
assays to validate function and specificity. These could then be tested for in vivo 
efficacy.  
 Future directions for the SOX2 project involve better understanding SOX2 
regulation of pro-survival pathways. Our data show that SOX2 knockdown leads 
to upregulation of EGFR (Figure 3.5). We hypothesize that this may be due to 
activation of Beta-Catenin signaling as a result of loss of SOX2 sequestration of 
this protein or loss of direct repression of transcription by SOX2. We need to test 
this by determining if SOX2 and Beta-Catenin interact in ALL cells and if SOX2 
knockdown leads to increased B-Catenin binding to DNA by ChIP-qPCR. 
Furthermore, ChIP-sequencing would reveal if SOX2 directly binds any genes to 
repress transcription of these pathways directly in ALL. 
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While we observe an upregulation of Egfr mRNA in Sox2 knockdown and 
GC resistant patient samples, we need to further validate that this pathway is active 
and if EGFR is the upstream receptor. To further test this model, we will evaluate 
functional activation of downstream pathways including phosphorylation of ERK1/2 
and phosphorylation of STAT proteins. Furthermore, we will evaluate if EGFR 
signaling is essential for GC resistance in Sox2 knockdown cells by using genetic 
and pharmacologic inhibition of this protein as well as inhibition of downstream 
JAK and MEK kinases. It is possible that pro-survival signaling in the context of 
SOX2 repression is not mediated by EGFR but rather by a cytokine receptor or 
other receptor tyrosine kinases, such as C-KIT. In addition to Egfr upregulation , 
we observe an increase in Kit ligand mRNA following Sox2  knockdown, 
suggesting that this ligand-receptor interaction may be important in GC resistance.  
We will first test EGFR and MAPK inhibitors in combination with dexamethasone 
to see if this sensitizes Sox2 knockdown cells to therapy. It would then be 
interesting to determine if these inhibitors re-sensitive relapse ALL cells to 




Figure 4.1 Model of ESRRB regulation of glucocorticoid signaling 
ALL cells exposed to no treatment or vehicle treatment do not undergo cell death 
due to their transformed state. Apoptotic gene promoters interact with their 
enhancer elements infrequently, leaving the transcription off or very low. When 
the chemotherapeutic dexamethasone is added, the glucocorticoid receptor (GR) 
is activated, enters the nucleus, and binds target genes at enhancer regions. 
This leads to recruitment of additional factors, including the cooperating 
transcription factor ESRRB. Enhancer elements and promoters now can interact 
and the GR and ESRRB cooperate to recruit co-activators and the transcription 
initiation complex to induce transcription of target genes, which include pro-
apoptotic genes like BIM to induce leukemic cell death. If dexamethasone is 
added to ALL cells in combination with an agonist to ESRRB which increases its 


































Figure 4.2 SOX2 represses pro-survival gene expression in ALL allowing 
dexamethasone-induced apoptosis 
SOX2 functions to inhibit EGFR mediated MAPK signaling, potentially through 
repression of the WNT signaling pathway. This repression is essential to inhibit 
pro-survival gene expression. If SOX2 is repressed, EGFR and downstream 
target genes are activated leading to survival signaling which inhibits the death 
























































Evaluating the efficacy of ESRRB agonist DY131 as a leukemia therapeutic 
in pre-clinical ALL models 
 
 My work in chapter II defines ESRRB as a cooperating transcription factor 
of the glucocorticoid receptor downstream of dexamethasone treatment. We then 
showed that the ESRRB agonist DY131 increases dexamethasone-induced 
apoptosis and gene expression in human ALL cell lines (Figure 2.14 A-C). 
Therefore, we wanted to examine the effects of this compound in vivo. 
 DY131 was identified as a selective agonist of ESRRB and ESRRG, which 
increases their transcriptional activity by stabilization and enlargement of the ligand 
binding domain for co-activator recuitment191–193. This compound was previously 
utilized for in vivo studies to examine effects of DY131 in pregnant mice, gastric 
cancer, and energy regulation166,264,288.  
 We first evaluated potential toxicity of the DY131 compound alone and in 
combination with dexamethasone treatment. We found no change in the weight of 
NSG (NOD-scid IL2Rgammanull) mice following administration of this compound 
and no gross alterations in organ appearance (Figure A.I.1 A,B). We first examined 
gene expression effects in normal thymocytes and found a significant increase in 
expression of GR target genes upon dual administration of dexamethasone and 
DY131 (Figure A.I.2 A). We then transplanted a tumor derived from our Tal1/Lmo2 
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model of T-ALL into syngeneic recipients. Prior to sacrifice we administered 
dexamethasone, DY131 or the combination and found that GR target genes were 
elevated in the thymic tumors (Figure A.I.2 B). Although these gene expression 
results were promising we found no significant differences in survival upon 
administration of DY131 (Figure A.I.2 C).  
 We also evaluated the efficacy of DY131 in vivo utilizing a patient derived 
xenograft of T-ALL cells. One million relapse T-ALL patient cells were transplanted 
into NSG mice. Engraftment was monitored by cheek bleed and flow cytometric 
analysis of Human CD45 (HCD45) expression on the peripheral white blood cells. 
Once the levels of HCD45 in the periphery reached over 20%, mice were 
randomized into 4 groups: vehicle, dexamethasone, DY131 or dexamethasone 
and DY131 dual treatment. All groups had the same average HCD45 burden at 
the start of treatment. Treatments were administered for 14 days and HCD45 was 
quantified at day 7 and day 14. HCD45 burden in the peripheral blood was 
significantly reduced by dexamethasone treatment, but no advantage was seen 
with the DY131 combination therapy (Figure A.I.3 A). We then scarified the animals 
and quantified leukemic burden by spleen weight and cellularity as well as bone 
marrow cellularity and peripheral white blood cell count. Furthermore, we 
quantified %HCD45 in the bone marrow and spleen. Utilizing these parameters we 
observe significant reduction in leukemic burden with dexamethasone treatment; 
however, DY131 and dexamethasone dual treatment does not alter leukemic 
burden more than dexamethasone alone (Figure A.I.3 B).  
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 DY131 has poor solubility and therefore precipitates in aqueous solution. 
For these reasons, it is possible that the levels of DY131 in the animal were not 
sufficient to induce leukemic cell death, as observed in vitro. Future directions for 
this project require altering the DY131 structure to improve in vivo efficacy while 
utilizing reporter-based assays to ensure alterations do not change its ability to 































Figure A.I.1 The ESRRB agonist DY131 does not alter mouse weight in vivo. 
Mice were treated with DMSO, DY131 (30 mg/kg), or Dexamethasone (15 mg/
kg) and DY131 in combination for 21 days. At day 21 mice were sacrificed and 
gross anatomy examined (A). Mice were weighed every 7 days for signs of 
weight loss as an indicator of drug toxicity (B).  


































Figure A.I.2 The ESRRB agonist DY131 increases dexamethasone induced 
gene expression in vivo but not survival. Wild-type (A) or  leukemic mice (B) 
were treated with vehicle, DY131, Dexamethasone or the combination for 3 
hours and thymocytes were harvested. Expression of GR target genes Nr3c1, 
Bcl2l11, and Tsc22d3 was analyzed by quantitative real-time PCR. Copy number 
was normalized to β-actin using the ΔΔCT. Mice were transplanted with a Tal1/
Lmo2 tumor (8936). After 7 days mice were treated with vehicle, DY131, 
Dexamethasone or the combination and survival was assayed. Kaplan-Meier 
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Figure A.I.3 The ESRRB agonist DY131 does not increase dexamethasone 
response in mice transplanted with a relapse T-ALL patient sample. NSG 
mice were transplanted with the relapse T-ALL sample classified as TLX-14. 
Human CD45+ blood cells were monitored by cheek bleed and flow cytometry. 
When mice reached an average of 20% leukemia burden they were divided into 
4 groups: Vehicle, DY131, dexamethasone or dual treatment. Mice were 
monitored by cheek bleed at 7 and 14 days for leukemia burden (A). At day 14 
mice were sacrificed and leukemic burden assessed by spleen weight, white 
blood cell count (WBC), bone marrow cellularity, spleen cellularity, and number of 
human CD45 positive cells in the spleen and bone marrow. While 
dexamethasone decreased the leukemic burden, no difference was observed in 




















































































































Examining the role of B12 as a toxic metabolite in leukemia cells in vivo 
 
 The toxic metabolite theory of cancer involves over-loading a cancer cell 
with metabolites that they naturally utilize. Dr. Dohoon Kim’s lab demonstrated this 
using the selenium metabolite to kill cancer cells289 and are now pursuing other 
candidates. In collaboration with Dr. Dohoon Kim and his post-doctoral associate 
Dr. Namgyu Lee, we evaluated vitamin B12 as a potential toxic metabolite and 
therapeutic in leukemia. Dr. Lee generated data which showed that high doses of 
the vitamin B12 derivate adenosylcobalamin is selectively toxic to human leukemia 
cell lines, including DND-41, KOPTK1, CUTTL1, K562, CEM and more. However, 
this treatment did not affect other human cancer cell lines such as HeLa cells, 
MCF-7, THLE2, PANC1 and more. Furthermore, we found that adenosylcobalmin 
was toxic to relapse patient samples in vitro. This finding led us to evaluate whether 
this toxicity could translate to in vivo studies.  
 NSG mice were engrafted with the relapse T-ALL sample classified as TLX-
14. HCD45 levels were monitored weekly by cheek bleed and flow cytometric 
analysis. Once HCD45 levels were an average of 5%, mice were randomized into 
either vehicle or adenosylcobalamin (B12) treatment groups. HCD45 was 
assessed at 2 weeks and 3 weeks of treatment and no difference was observed 
between vehicle and B12 groups (Figure A.II.1 A). After 3 weeks of treatment mice 
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were sacrificed at spleen weight quantified, similar to HCD45 data, no difference 
was observed between treatment groups (Figure A.II.1 B). 
 Our data suggest that vitamin B12 is not a therapeutically relevant 
candidate in vivo. Observations of mouse urine following B12 dosage suggest 
rapid excretion of the compound as indicated by a red color change. Chemical 
alterations that prevent rapid metabolism could improve the in vivo efficacy of 
































Figure A.II.1 Adenosylcobalamin (B12) is not an effective leukemia 
therapeutic in vivo. NSG mice were transplanted with the relapse T-ALL sample 
TLX-14. When mice reached over 5% leukemic burden in the periphery they 
were treated with vehicle or B12 for 21 days. Human CD45 in the periphery was 
monitored (A). Mice were sacrificed after 3 weeks of treatment and leukemic 
burden assessed by spleen weight (B). 














































Attempts to identify critical markers and pathways in leukemia initiating cells 
by single-cell RNA-sequencing 
*Figures in this section were generated in collaboration with Kevin O’Connor 
 
 Our lab and others have previously established that only a subset of 
leukemic cells in our Tal1/Lmo2 mouse model have the ability to induce leukemia. 
These cells have been classified as leukemia-initiating cells and are enriched in 
the DN3 subset of thymocyte progenitors74,75. These cells depend on MYC and 
NOTCH1 signaling77,78. However, more work is necessary to further characterize 
this population in hopes of better targeting it.  
 In order to fully characterize all cell populations in thymic tumors derived 
from the Tal1/Lmo2 mouse model, we performed single cell RNA-sequencing 
utilizing the 10x genomics platform. We sequenced wildtype thymocytes, pre-
leukemic thymocytes, and leukemic thymocytes and clustered the DN3 cells using 
UMAP to visualize the heterogeneity in these cell types (Figure A.III.1 A). 
Interestingly we identified a cluster of cells in the DN3 section present at high 
frequency in the tumor and pre-leukemic sample which exhibited low Ki67 
expression, a proliferation marker (Figure A.III.1 B). While these cells maintain high 
NOTCH1 expression, it appears they may be a rare dormant population of tumor 
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cells. Interestingly, dormant leukemic cells have been implicated in therapy 
resistance in patient samples290.  
 As dormant cells may be important in relapse and resistance, we wanted to 
define key proteins in this population. We first characterized cell surface proteins 
on this dormant cell population, which were increased compared to other cell 
populations. Cell surface proteins can be targeted by inhibitors or used as antigens 
for CAR-T-cell therapy making them appealing candidates to analyze. We 
identified 16 cell surface proteins differentially expressed on our dormant cell 
population utilizing surfaceome analysis, previously developed to analyze cell 
surface markers on L-ICs in an Lmo2 only mouse model291. One of the most 
promsing hits from this analysis was to the non-canonical WNT receptor RYK, 
which has been previously shown to mark acute leukemic cells vs. wildtype 
cells292. This is consistent with our data which show Ryk expression dramatically 
increased in thymic tumors from Tal1/Lmo2 mice compared to wildtype thymocytes 
(Figure A.III.1 C). 
 This receptor has been previously implicated in regulation of proliferation 
and apoptosis in hematopoietic stem cells293; furthermore, we detect significant 
increases in RYK expression in T-ALL patient cells compared to WT cells (Figure 
A.III.1 D),  and so we wanted to functionally test if it was important in L-ICs. The 
frequency of leukemia-initiating cells can be tested by in vivo limiting dilution 
analysis experiments followed by analysis with ELDA software294. We knocked 
down Ryk in leukemic samples using a GFP tagged retroviral-shRNA and 
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transplanted GFP+ cells into syngeneic recipients in limiting dilution alongside 
control shRNAs targeting Renilla and Myc (Figure A.III.1 E). This preliminary study 
utilized small mouse numbers but still found a 3 fold shift in L-IC frequency upon 
Ryk knockdown (Figure A.III.1 E), suggesting RYK may play a role in L-IC 
maintenance or proliferation. Importantly knockdown of Myc resulted in depletion 
of the L-IC population as our lab previously showed77. 
 These studies will be repeated with increased mouse numbers to further 
test the role of RYK in L-IC function. It will also be interesting to determine what 
ligands are signaling through RYK to activate this pathway. Lastly, we will test 
monoclonal antibodies to RYK in patient-derived xenografts to determine if this is 















































































































































































































Cell Dose shRenilla shRyk shMyc
1x105 2/3 2/3 0/3
1x104 2/3 0/3 0/3
1x103 1/3 0/3 0/3
Total 5/9 2/9 0/9


















Figure A.III.1 Single Cell analysis of mouse T-lymphoblastic leukemia 
reveals RYK as a putative regulator of the L-IC. Pre-leukemic (pl), thymic 
tumors (tumor) or wild-type thymus (wt) were harvested and run on the 10x 
genomics platform to achieve a single cell transcriptional profile of each thymus. 
Cells expressing CD25 but not CD4, CD8, or CD44 were clustered using UMAP 
and revealed 6 cell clusters (A). Cluster 2,3 and 4 were enriched in the tumor 
samples and all expressed high levels of NOTCH1; however, cluster 3 exhibited 
low levels of Ki67 (B). Analysis of cell surface proteins revealed that the non-
canonical WNT receptor RYK was enriched in cluster 3 and RT-qPCR shows it 
overexpressed in thymic tumors (C). Microarray analysis of T-ALL patients shows 
elevated RYK expression compared to normal thymus (D). Tal1/Lmo2 thymic 
tumor cells were infected with shRNAs targeted against Renilla, Ryk, or Myc and 
transplanted in limiting dilution. Survival and L-IC frequency were noted and an 





Repression of cAMP signaling mediates glucocorticoid resistance 
*Data in this section were generated in collaboration with Justine Roderick and are 
part of the submitted manuscript “Roderick, JE., Gallagher, KM., et al. 
Prostaglandin E2 stimulates cAMP signaling and re-sensitizes human leukemia 
cells to glucocorticoid-induced cell death.” 
  
As my contribution to the manuscript “Prostaglandin E2 stimulates cAMP 
signaling and re-sensitizes human leukemia cells to glucocorticoid-induced cell 
death” by Roderick et al. I validated repression of the cAMP signaling pathway as 
a mechanism of glucocorticoid resistance in ALL with a focus on knockdown of the 
G protein alpha subunit GNAS. 
Following a whole genome shRNA screen for proteins whose loss mediates 
GC resistance in ALL, I validated several of the screen hits by dexamethasone 
dose response studies (Figure A.IV.1 A) We found that shRNA sreen hits shifted 
the dexamethasone GI50 to varying degrees (Figure A.IV.1 A;  left). Interestingly 
we found several hits in the shRNA screen were part of the cAMP signaling 
pathway (Figure A.IV.1 B; left).  cAMP signaling involves activation of G-protein 
coupled receptors at the cell membrane. This activation allows release of the G 
protein alpha subunit of the receptor which can bind and activate adenylyl cyclase 
to trigger ATP to cAMP conversion. cAMP can then activate PKA and CREB to 
induce transcriptional changes295. Our shRNA screen identified knockdown of G-
protein coupled receptors, G-protein subunits, adenylyl cyclases, and Creb as 
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mechanisms of glucocorticoid resistance. We validated all hits in the cAMP 
signaling pathway by knocking down each protein by shRNA and evaluating 
dexamethasone response by Annexin V/7AAD staining (Figure A.IV.1 B; right).  
To further validate repression of cAMP signaling as a mechanism of 
glucocorticoid resistance, we utilized a dexamethasone sensitive mouse T-ALL 
cell line from our lab’s Tal1/Lmo2 mouse model of T-ALL to knockdown the G-
protein alpha subunit Gnas, which is critical in activation of cAMP signaling296. I 
achieved significant knockdown of Gnas with 2 independent shRNAs (Figure 
A.IV.2 A). I then assayed the dexamethasone response of these cell lines. Dose 
responses show significant shifts in the dexamethasone GI50 upon Gnas 
knockdown (Figure A.IV.2 B). Furthermore, Annexin V/7AAD quantification of 
apoptosis following dexamethasone treatment showed significant reduction in 
cellular apoptosis following GNAS repression (Figure A.IV.2 C). We also found that 
a reduction in Gnas levels resulted in abrogation of dexamethasone-induced gene 
expression of the target genes Nr3c1, Btg1, Klf13, Tsc22d3 and Bcl2l11 (Figure 
A.IV.2 D). We also confirmed these findings in an additional mouse T-ALL cell line 
5059 (Figure A.IV.2 E-H). These data validate reduction in Gnas expression as a 
mechanism of resistance to dexamethasone in mouse T-ALL cell lines. 
 To ensure that this finding could translate to human ALL, we generated 
GNAS deficient NALM-6 cells and assayed their dexamethasone response. 
Similar to our studies in mouse, we find a shift in the dexamethasone response 
upon knockdown (Figure A.IV.3 A,B). Furthermore, we find that GNAS repression 
 155 
 
inhibits induction of canonical dexamethasone regulated genes NR3C1, BCL2l11, 
and TSC22D3 (Figure A.IV.3 C). This suggests that signaling via GNAS is required 
for normal dexamethasone-induction of gene expression, including auto-induction 
of the GR itself, which may be explained by a predicted CREB site in an NR3C1 
enhancer region. 
Due to our findings surrounding repression of cAMP signaling in resistance 
to glucocorticoids. We went on to test if activation of cAMP signaling could re-
sensitize cells to glucocorticoid therapy. In fact using, forskolin, cAMP analogues, 
and dmPGE2, our work shows that re-activation of cAMP signaling in relapsed ALL 
can re-sensitize patient samples to glucocorticoid therapy in vitro and in vivo 
(Roderick et al. Blood. In revision). This study builds on previous work which 
showed that cAMP signaling could increase GR signaling in resistant CEM cells 
and increase apoptosis in B-CLL297,298. Furthermore, cAMP signaling had been 












Figure A.IV.1 Components of the cAMP signaling pathway mediate 
glucocorticoid resistance. Following an shRNA screen for genes whose loss 
mediates glucocorticoid resistance. We infected a dexamethasone sensitive 
mouse T-ALL cell line with individual shRNAs targeting candidate genes and 
evaluated their effect on the dexamethasone response at various doses after 48 
hours of treatment using MTS reagent (A). Several putative glucocorticoid 
resistance genes were members of the cAMP signaling pathway (B; left, red 
text). We further validated the glucocorticoid response after knockdown of cAMP 
components by treating knockdown cell lines with dexamethasone for 48 hours 
and evaluating apoptosis by Annexin V/7AAD staining followed by flow cytometry 
(B;right). The results are averages of three independent experiments and error 
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Figure A.IV.2 Repression of the G-alpha subunit Gnas mediates 
glucocorticoid resistance in ALL. Mouse T-ALL cells (1390) were transduced 
with lentiviruses expressing a Non-silencing (NS) control or two independent 
shRNAs targeting mouse Gnas (56,60) and Gnas mRNA expression was 
analyzed by quantitative real-time PCR. Copy number was normalized to β-actin 
using the ΔΔCT (A). Knockdown of Gnas in mouse T-ALL cells (1390) 
significantly shifts the dexamethasone GI50. Non-silencing cells or cells deficient 
for GNAS were cultured in increasing concentrations of dexamethasone for 48 
hours and viability was assayed by MTS. Absorbance values were normalized to 
vehicle control (B). Gnas knockdown results in resistance to dexamethasone-
induced apoptosis. Mouse T-ALL cells expressing NS or Gnas-shRNAs were 
cultured with dexamethasone (50nM) for 2 days and apoptosis was assayed by 
Annexin V-FITC/7-AAD staining followed by flow cytometry (C). Nr3c1, Bcl2l11, 
Tsc22d3, Btg1, and Klf13 are GR-regulated genes dependent on GNAS for their 
expression. Control or Gnas knockdown cells (2 independent shRNAs) were 
treated with dexamethasone for 6 hours and Nr3c1, Bcl2l11, Tsc22d3, Btg1, and 
Klf13 mRNA expression was analyzed by quantitative real-time PCR. Copy 
number was normalized to β-actin using the ΔΔCT. Expression levels are 
compared to knockdown of the GR (Nr3c1) as a control (D). Mouse T-ALL cells 
(5059) were transduced an shRNA targeting mouse Gnas (56) and Gnas mRNA 
expression was analyzed by quantitative real-time PCR. Copy number was 
normalized to β-actin using the ΔΔCT (E). Knockdown of Gnas in mouse T-ALL 
cells (5059) significantly shifts the dexamethasone GI50. Non-silencing cells or 
cells deficient for GNAS were cultured in increasing concentrations of 
dexamethasone for 48 hours and viability was assayed by MTS. Absorbance 
values were normalized to vehicle control (F). Gnas knockdown results in 
resistance to dexamethasone-induced apoptosis. Mouse T-ALL cells expressing 
NS or Gnas-shRNA were cultured with dexamethasone (10nM) for 2 days and 
apoptosis was assayed by Annexin V-FITC/7-AAD staining followed by flow 
cytometry (G). Control or Gnas knockdown cells were treated with 
dexamethasone for 6 hours and Nr3c1, Bcl2l11, Klf13, and Zfp36l2 mRNA 
expression was analyzed by quantitative real-time PCR. Copy number was 
normalized to β-actin using the ΔΔCT (H). The results are averages of three 








Figure A.IV.3 GNAS knockdown in human B-ALL cell lines NALM-6 results 
in dexamethasone resistance. Human B-ALL cells NALM-6 were transduced 
with lentiviruses expressing a Non-silencing (NS) control or two independent 
shRNAs targeting human GNAS (413,417). Knockdown of GNAS shifts the 
dexamethasone dose response. Non-silencing cells or cells deficient for GNAS 
were cultured in increasing concentrations of dexamethasone for 72 hours and 
viability was assayed by Cell Titer Glo normalized to vehicle control (A). 
Knockdown of human GNAS was confirmed by analyzing GNAS mRNA 
expression by quantitative real-time PCR. Copy number was normalized to β-
actin using the ΔΔCT (B) NR3C1, BCL2L11, and TSC22D3 are GR-regulated 
genes dependent on GNAS for their expression. Control or GNAS knockdown 
cells (2 independent shRNAs) were treated with dexamethasone for 6 hours and 
target gene mRNA expression was analyzed by quantitative real-time PCR. Copy 
number was normalized to β-actin using the ΔΔCT (C).


























































































































































List of shRNA sequences 
Table A.1 
Organism shRNA name shRNA sequence 
Mouse Esrrb 1 GCCGAGGACTATATCATGGAT 
Mouse Esrrb 2 CGATTCATGAAATGCCTCAAA 
Human ESRRB 1 GCACAAACTCTTCCTGGAGAT 
Human ESRRB 2 CCCATACCTGAGCTTACAAAT 
Mouse Nr3c1 1 CTGGAGATACAATCTTATCAA 
Human NR3C1 1 CCTGGATGTTTCTTATGGCAT 
Mouse Sox2 CGAGATAAACATGGCAATCAA 
Human SOX2 1 CGAGATAAACATGGCAATCAA 
Human  SOX2 2 GCACATGAACGGCTGGAGCAA 
Mouse Pou5f1 CCTACAGCAGATCACTCACAT 













List of Primers 
Table A.2  
Organis
m 
Gene Forward Primer Reverse Primer 
Mouse  Actin CGAGGCCCAGAGCAAGAGAG  CGGTTGGCCTTAGGGTTCAG 
Mouse  Esrrb AACCGAATGTCGTCCGAAGAC  GTGGCTGAGGGCATCAATG 
Mouse  Nr3c1 GACTCCAAAGAATCCTTAGCTC
C 
CTCCACCCCTCAGGGTTTTAT 
Mouse  Bcl2l11 GACAGAACCGCAAGGTAATCC ACTTGTCACAACTCATGGGTG 
Mouse  Tsc22d3 ACCACCTGATGTACGCTGTG CAGCCGGGACTGGAACTTT 
Mouse  Bcl2l1 GGAAGGCGTAGACAAGGAGAT
G 
GCATTGTTCCCGTAGAGATCC 
Mouse  Rag1 ACCCGATGAAATTCAACACCC  CTGGAACTACTGGAGACTGTTC
T 
Mouse  Klf3 GAAGCCCAACAAATATGGGGT  GGACGGGAACTTCAGAGAGG 
Mouse  Sox2 GCGGAGTGGAAACTTTTGTCC  CGGGAAGCGTGTACTTATCCTT  
Mouse  Pou5f1 AGAGGATCACCTTGGGGTACA  CGAAGCGACAGATGGTGGTC  
Mouse  Nanog  TCTTCCTGGTCCCCACAGTTT  GCAAGAATAGTTCTCGGGATGA
A  
Human  ACTIN CGCGAGAAGATGACCCAGAT  GATAGCACAGCCTGGATAGCAA
C 







Human  ESRRB ATCAAGTGCGAGTACATGCTC CGCCTCCGTTTGGTGATCTC 












Human  Nr3c1 
ERRE 1 
GGAAACCCGATCATTATGCCT  TTGGACGAGGGCAGAACTAG 




Human  Bcl2l1l 
ERRE 
ACTTAGACGGCACCTTCGAG  CCCCAAAACTCTCGCTGAAA 
Human  Tsc22d3 
ERRE 
GGGCTGAGGTAGGGAAAAGT  AACAAGGAAGCAGATTGGCC 
Human  Tsc22d3 
negative 
AATATTCCCGGTTGCATCAC  AAGGCACCAGAGACTTGAGG 
Human Bcl2l11 
negative 
GCGAAGAGCAAAGTTCGTCC  CGGCTAAGTAGACTCGGAGG 
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